[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 316
1. Bäcklund LM, Grandér D, Brandt L, Hall P, Ekbom A: Parathyroid adenoma and primary CNS tumors. Int J Cancer; 2005 Mar 1;113(6):866-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parathyroid adenoma and primary CNS tumors.
  • There are several case reports of MEN Type 1-associated central nervous system (CNS) tumors.
  • To determine if there is an association between parathyroid adenomas and CNS tumors, we used Swedish registry data to identify all individuals operated on for parathyroid adenomas between 1958-99 (n = 12,468).
  • Follow-up for the occurrence of CNS tumors in these individuals was through linkage with the Swedish Cancer Registry.
  • There were 70 observed cases of a CNS tumor diagnosed after a parathyroid adenoma, to be compared to 35 expected (standard incidence ratio [SIR] = 2.0; 95% confidence interval [CI] = 1.5-2.5).
  • These results strongly indicate an association between these tumor forms that may be genetic, environmental (such as radiation) or a combination of both.
  • [MeSH-major] Adenoma / epidemiology. Central Nervous System Neoplasms / epidemiology. Parathyroid Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Neoplasms, Second Primary / epidemiology. Registries. Retrospective Studies. Sweden / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15515018.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


2. Wernicke AG, Sherr DL, Schwartz TH, Pannullo SC, Stieg PE, Boockvar JA, Ivanidze J, Moliterno JA, Parashar B, Trichter S, Sabbas AM, Nori D: Feasibility and safety of GliaSite brachytherapy in treatment of CNS tumors following neurosurgical resection. J Cancer Res Ther; 2010 Jan-Mar;6(1):65-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility and safety of GliaSite brachytherapy in treatment of CNS tumors following neurosurgical resection.
  • PURPOSE: To investigate feasibility and safety of GliaSite brachytherapy for treatment of central nervous system (CNS) tumors following neurosurgical resection.
  • MATERIALS AND METHODS: In the period from 2004 to 2007, 10 consecutive adult patients with recurrent, newly diagnosed, and metastatic brain malignancies underwent GliaSite brachytherapy following maximally safe neurosurgical resection.
  • [MeSH-major] Brachytherapy / methods. Brain Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Feasibility Studies. Female. Humans. Male. Middle Aged. Neurosurgical Procedures. Pilot Projects. Radiotherapy Dosage. Radiotherapy, Adjuvant / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479550.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] India
  •  go-up   go-down


3. Arora RS, Alston RD, Eden TO, Estlin EJ, Moran A, Birch JM: Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in England. Neuro Oncol; 2009 Aug;11(4):403-13
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in England.
  • Around 25% of all tumors in those 0-14 years of age and 9% in those 15-24 years of age involve the CNS.
  • In adults 25-84 years of age, the proportion of CNS tumors is 2%; 5-year overall survival is 10%-15%; and survivors have considerable morbidity.
  • Comprehensive up-to-date population-based incidence data on these tumors are lacking.
  • We present incidence rates for primary CNS tumors based on data derived from the high-quality national cancer registration system in England.
  • A total of 54,336 CNS tumors of malignant, benign, and uncertain behavior were registered across the whole of England from 1995 through 2003.
  • This is higher than previously reported for England because it includes nonmalignant CNS tumors and hence gives a more accurate picture of burden of disease.
  • In this article, we describe the changing patterns in the epidemiology of primary CNS tumors in these three age groups with respect to sex, tumor behavior, and histology using the current WHO classification.
  • [MeSH-major] Brain Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. England / epidemiology. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Risk Factors. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):168-74 [10634382.001]
  • [Cites] Br J Cancer. 2007 Dec 3;97(11):1588-94 [17987032.001]
  • [Cites] Am J Otol. 2000 Sep;21(5):690-4 [10993460.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1548-56 [11920513.001]
  • [Cites] Br J Neurosurg. 2002 Apr;16(2):140-5 [12046732.001]
  • [Cites] Med Pediatr Oncol. 2002 Sep;39(3):190-4 [12210449.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):278-99 [12356358.001]
  • [Cites] J Neurooncol. 2002 Oct;60(1):61-9 [12416547.001]
  • [Cites] Br J Cancer. 2002 Nov 18;87(11):1267-74 [12439716.001]
  • [Cites] Dev Med Child Neurol. 2003 May;45(5):308-14 [12729144.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):168-78 [12816723.001]
  • [Cites] Int J Cancer. 2004 Jan 20;108(3):450-5 [14648713.001]
  • [Cites] Neuroepidemiology. 2004 May-Jun;23(3):101-9 [15084778.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Jun;75 Suppl 2:ii12-7 [15146034.001]
  • [Cites] Mayo Clin Proc. 1978 Oct;53(10):641-3 [713594.001]
  • [Cites] J Neurosurg. 1985 Dec;63(6):881-9 [4056902.001]
  • [Cites] Zentralbl Neurochir. 1987;48(2):120-3 [3673352.001]
  • [Cites] Childs Nerv Syst. 1991 Aug;7(4):177-82 [1933913.001]
  • [Cites] Am J Epidemiol. 1992 Jun 15;135(12):1349-57 [1510081.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Sep;41(3):359-64 [7893282.001]
  • [Cites] J Neurooncol. 1995;25(1):67-71 [8523091.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):827-33 [8608471.001]
  • [Cites] Neurol Med Chir (Tokyo). 1999 Jan;39(1):59-107 [10093464.001]
  • [Cites] Laryngoscope. 1999 May;109(5):736-40 [10334223.001]
  • [Cites] Int J Cancer. 2005 Dec 20;117(6):996-1001 [15986431.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):1-11 [16443943.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):27-37 [16443945.001]
  • [Cites] Acta Neurochir (Wien). 2006 Aug;148(8):865-71; discussion 871 [16791430.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(13):2064-80 [16919771.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4754-7 [16966685.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):81-9 [17482475.001]
  • [Cites] Health Stat Q. 2007 Autumn;(35):78-83 [17894201.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Apr;85(4):1420-5 [10770176.001]
  • (PMID = 19033157.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2743220
  •  go-up   go-down


Advertisement
4. Carroll TJ, Horowitz S, Shin W, Mouannes J, Sawlani R, Ali S, Raizer J, Futterer S: Quantification of cerebral perfusion using the "bookend technique": an evaluation in CNS tumors. Magn Reson Imaging; 2008 Dec;26(10):1352-9
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantification of cerebral perfusion using the "bookend technique": an evaluation in CNS tumors.
  • We have compared the quantitative SE-EPI with GRE-EPI in a series of patients with central nervous system (CNS) tumors.
  • We conclude that measuring qCBV using the bookend technique with SE-EPI images is possible and may be a viable alternative to GRE-EPI in the evaluation of CNS tumors.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stroke. 1984 Jul-Aug;15(4):635-41 [6611613.001]
  • [Cites] J Comput Assist Tomogr. 1980 Dec;4(6):727-36 [6971299.001]
  • [Cites] Magn Reson Med. 1992 Jan;23(1):21-30 [1734180.001]
  • [Cites] Magn Reson Med. 1991 Dec;22(2):293-9; discussion 300-3 [1812360.001]
  • [Cites] Magn Reson Med. 1994 Jun;31(6):601-10 [8057812.001]
  • [Cites] Radiology. 1994 Dec;193(3):637-41 [7972800.001]
  • [Cites] Radiology. 1996 Oct;201(1):106-12 [8816529.001]
  • [Cites] Magn Reson Med. 1996 Nov;36(5):715-25 [8916022.001]
  • [Cites] Magn Reson Med. 1996 Nov;36(5):726-36 [8916023.001]
  • [Cites] Magn Reson Med. 1996 Dec;36(6):858-67 [8946351.001]
  • [Cites] Magn Reson Med. 1997 Oct;38(4):591-603 [9324327.001]
  • [Cites] Top Magn Reson Imaging. 2004 Oct;15(5):279-89 [15627003.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Feb;26(2):266-73 [15709123.001]
  • [Cites] J Magn Reson Imaging. 2005 May;21(5):512-9 [15834910.001]
  • [Cites] Radiology. 2006 Feb;238(2):658-67 [16396838.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Apr;27(4):859-67 [16611779.001]
  • [Cites] Magn Reson Med. 2006 Jul;56(1):138-45 [16767742.001]
  • [Cites] Magn Reson Med. 2007 Dec;58(6):1232-41 [17969025.001]
  • [Cites] Magn Reson Med. 1999 Nov;42(5):952-62 [10542355.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Aug;22(7):1306-15 [11498419.001]
  • [Cites] Magn Reson Med. 2001 Oct;46(4):735-47 [11590650.001]
  • [Cites] Magn Reson Med. 2002 Jun;47(6):1110-20 [12111957.001]
  • [Cites] Magn Reson Med. 2002 Jun;47(6):1202-10 [12111967.001]
  • [Cites] Radiology. 2003 May;227(2):593-600 [12663823.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 May;25(5):746-55 [15140713.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Oct;25(9):1524-32 [15502131.001]
  • [Cites] Biophys J. 1974 Aug;14(8):583-606 [4853385.001]
  • [Cites] Magn Reson Med. 1990 May;14(2):249-65 [2345506.001]
  • (PMID = 18538523.001).
  • [ISSN] 0730-725X
  • [Journal-full-title] Magnetic resonance imaging
  • [ISO-abbreviation] Magn Reson Imaging
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS049395-01A2; United States / NIBIB NIH HHS / EB / T32 EB005170-03; United States / NIBIB NIH HHS / EB / T32 EB005170; United States / NINDS NIH HHS / NS / R01NS049395-01A2; United States / NIBIB NIH HHS / EB / EB005170-03; United States / NINDS NIH HHS / NS / R01 NS049395-01A2; United States / NINDS NIH HHS / NS / R01 NS049395
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  • [Other-IDs] NLM/ NIHMS81510; NLM/ PMC2612563
  •  go-up   go-down


5. Reismüller B, Azizi AA, Peyrl A, Heinrich M, Gruber-Olipitz M, Luckner D, Rothschild KV, Slavc I: Feasibility and tolerability of bevacizumab in children with primary CNS tumors. Pediatr Blood Cancer; 2010 May;54(5):681-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility and tolerability of bevacizumab in children with primary CNS tumors.
  • BACKGROUND: Bevacizumab, an antibody to the vascular endothelial growth factor, has demonstrated anti-cancer activity in a number of solid tumors.
  • Fear of intratumoral hemorrhage, however, has slowed its introduction into the treatment of central nervous system (CNS) tumors.
  • Most patients had recurrent/progressive disease, 25 high-grade and 5 low-grade tumors.
  • CONCLUSIONS: Bevacizumab appears to be safe for children with primary CNS tumors.
  • Hypertension occurred less frequently than in adult patients.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Central Nervous System Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bevacizumab. Brain Neoplasms / drug therapy. Brain Neoplasms / pathology. Child. Child, Preschool. Drug-Related Side Effects and Adverse Reactions. Feasibility Studies. Female. Humans. Infant. Lymphopenia / chemically induced. Male. Proteinuria / chemically induced. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20066713.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


6. Taylor AJ, Little MP, Winter DL, Sugden E, Ellison DW, Stiller CA, Stovall M, Frobisher C, Lancashire ER, Reulen RC, Hawkins MM: Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. J Clin Oncol; 2010 Dec 20;28(36):5287-93
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study.
  • PURPOSE: CNS tumors are the most common second primary neoplasm (SPN) observed after childhood cancer in Britain, but the relationship of risk to doses of previous radiotherapy and chemotherapy is uncertain.
  • Linkage to national, population-based cancer registries identified 247 SPNs of the CNS.
  • RESULTS: There were 137 meningiomas, 73 gliomas, and 37 other CNS neoplasms included in the analysis.
  • The risk of glioma/primitive neuroectodermal tumors increased linearly with dose of radiation, and those who had CNS tissue exposed to at least 40 Gy experienced a risk four-fold that experienced by those who had CNS tissue unexposed.
  • CONCLUSION: The largest-ever study, to our knowledge, of CNS tumors in survivors of childhood cancer indicates that the risk of meningioma increases rapidly with increased dose of radiation to meningeal tissue and with increased dose of intrathecal methotrexate.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21079138.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / ZIA CP010131-18; United Kingdom / Cancer Research UK / / ; United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ NIHMS533866; NLM/ PMC4809645
  •  go-up   go-down


7. Crawford JR, Santi MR, Cornelison R, Sallinen SL, Haapasalo H, MacDonald TJ: Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors. J Neurooncol; 2009 Oct;95(1):49-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors.
  • The purpose is to determine the incidence of active and latent human herpesvirus-6 (HHV-6) infection in a large cohort of adult primary and recurrent CNS tumors.
  • We screened a tissue microarray (TMA) containing more than 200 adult primary and recurrent CNS tumors with known clinical information for the presence of HHV-6 DNA by in situ hybridization (ISH) and protein by immunohistochemistry (IHC).
  • One hundred six of 224 (47%) CNS tumors were positive for HHV-6 U57 Major Capsid Protein (MCP) gene by ISH compared to 0/25 non tumor control brain (P = 0.001).
  • Fourteen of 30 (47%) tumors were HHV-6 MCP positive by nested PCR compared to 0/25 non-tumor brain controls (P = 0.001), revealing HHV-6 Variant A in 6 of 14 samples.
  • HHV-6A/B early (p41) and late (gp116/64/54) antigens were detected by IHC in 66 of 277 (24%) (P = 0.003) and 84 of 282 (35%) (P = 0.002) tumors, respectively, suggesting active infection.
  • Glial tumors were 3 times more positive by IHC compared to non glial tumors for both HHV-6 gp116/64/54 (P = 0.0002) and HHV-6 p41 (P = 0.004).
  • HHV-6 early and late antigens are detected in adult primary and recurrent CNS tumors more frequently in glial tumors.
  • We hypothesize that the glial-tropic features of HHV-6 may play an important modifying role in tumor biology that warrants further investigation.
  • [MeSH-major] Antigens, Viral. Central Nervous System Neoplasms / genetics. Central Nervous System Neoplasms / virology. Glioma / genetics. Glioma / virology. Herpesvirus 6, Human / isolation & purification
  • [MeSH-minor] Adult. Antigens, CD / metabolism. CD48 Antigen. Capsid Proteins / genetics. Capsid Proteins / metabolism. Humans. Survival Analysis. Viral Envelope Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19424665.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / K12NS052159-01A
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Viral; 0 / CD48 Antigen; 0 / Capsid Proteins; 0 / Viral Envelope Proteins
  •  go-up   go-down


8. Seymour ZA, Panigrahy A, Finlay JL, Nelson MD Jr, Blüml S: Citrate in pediatric CNS tumors? AJNR Am J Neuroradiol; 2008 May;29(5):1006-11
Hazardous Substances Data Bank. CITRIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Citrate in pediatric CNS tumors?
  • BACKGROUND AND PURPOSE: In a subset of in vivo MR spectra acquired from pediatric brain tumors, we have observed an unassigned peak.
  • The goal of this study was to determine the molecule of origin, and the prevalence and concentration of this chemical in various pediatric brain tumors.
  • MATERIALS AND METHODS: Single-voxel point-resolved spectroscopy (PRESS) spectra from 85 patients with brain tumors and 469 control subjects were analyzed.
  • CONCLUSION: MR signal consistent with citrate was observed in pediatric brain tumors and in the developing brain of infants younger than 6 months.
  • [MeSH-major] Brain / metabolism. Brain Neoplasms / metabolism. Citric Acid / metabolism. Magnetic Resonance Spectroscopy / methods
  • [MeSH-minor] Adolescent. Adult. Biomarkers / metabolism. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18272551.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA97452-02
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 2968PHW8QP / Citric Acid
  •  go-up   go-down


9. Thuppal S, Propp JM, McCarthy BJ: Average years of potential life lost in those who have died from brain and CNS tumors in the USA. Neuroepidemiology; 2006;27(1):22-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Average years of potential life lost in those who have died from brain and CNS tumors in the USA.
  • The aim of this study was to quantify the impact of all primary malignant and nonmalignant brain and central nervous system (CNS) tumors on mortality in the USA in terms of years of life lost, an indicator of premature mortality in the population.
  • Person-years of potential life lost (PYPLL) and average years of potential life lost (AYPLL) were calculated for all deaths due to brain and CNS tumors as an underlying cause.
  • 16,819 deaths due to brain and CNS tumors occurred in 2001, leading to a total loss of 357,483 person-years of life and an average loss of 21.3 years (AYPLL).
  • Malignant tumors led to an AYPLL of 25 years, which was significantly higher than the AYPLL of 19 years due to nonmalignant tumors.
  • The relative impact of tumors arising in the various anatomical sites in the brain and CNS among adults and among children was not similar.
  • The use of population survival indicators, such as PYPLL and AYPLL, will help better understanding of the effect of racial, ethnic, gender and age differences on the mortality due to malignant and nonmalignant brain and CNS tumors.
  • [MeSH-major] Central Nervous System Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Brain Neoplasms / mortality. Child. Female. Humans. Male. Middle Aged. Prevalence. Registries. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770081.001).
  • [ISSN] 0251-5350
  • [Journal-full-title] Neuroepidemiology
  • [ISO-abbreviation] Neuroepidemiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


10. Morris EB, Gajjar A, Okuma JO, Yasui Y, Wallace D, Kun LE, Merchant TE, Fouladi M, Broniscer A, Robison LL, Hudson MM: Survival and late mortality in long-term survivors of pediatric CNS tumors. J Clin Oncol; 2007 Apr 20;25(12):1532-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and late mortality in long-term survivors of pediatric CNS tumors.
  • PURPOSE: To describe the pattern of survival and late mortality among contemporary long-term survivors of pediatric CNS tumor.
  • PATIENTS AND METHODS: The study population comprised 643 pediatric patients with primary CNS tumor treated at St Jude Children's Research Hospital (Memphis, TN) from 1985 to 2000 who survived > or = 5 years from diagnosis.
  • Patients were classified according to primary tumor type, location of tumor, and survival.
  • A significant difference in the survival rates according to original tumor type (P = .001) was seen.
  • Sixty-six (10%) of 643 patients experienced late mortality: 38 patients (58%) died of progressive disease while 14 patients (21%) died of second malignant tumor.
  • Twelve patients (18%), predominantly with diencephalic tumor location, died of a specific medical cause: cardiovascular disease (n = 2), cerebrovascular accident (n = 1), metabolic collapse and/or sepsis (n = 7), respiratory failure (n = 1), or shunt malfunction (n = 1).
  • CONCLUSION: Late mortality occurs in a substantial number of long-term survivors of pediatric CNS tumors and is most influenced by the initial tumor histopathology.
  • [MeSH-major] Cause of Death. Central Nervous System Neoplasms / mortality. Survivors / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Child. Child, Preschool. Cohort Studies. Disease Progression. Disease-Free Survival. Female. Humans. Incidence. Male. Neoplasm Staging. Prognosis. Registries. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17442996.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 21765
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Butturini A, Frappaz D: The challenges of high-dose chemotherapy in CNS tumors. Pediatr Blood Cancer; 2010 Apr;54(4):652-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The challenges of high-dose chemotherapy in CNS tumors.
  • High-dose, myeloablative chemotherapy with hematopoietic stem cell rescue is used in children and young adults with brain tumors for which conventional therapy is either excessively toxic (e.g., radiotherapy in infants) or ineffective.
  • We will consider the difficulties in analyzing published data and the challenges of designing effective clinical trials that test high-dose chemotherapy in patients with brain tumors.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Central Nervous System Neoplasms / drug therapy
  • [MeSH-minor] Child. Combined Modality Therapy. Hematopoietic Stem Cell Transplantation. Humans. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20146215.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 4
  •  go-up   go-down


12. Gercovich FG, Gil Deza E, Martin Reina G, Garcia Gerardi C, Abal M, Santillan D, Tognelli F, Calarame J, Rivarola E, Morgenfeld E: 300% increase rate in juvenile cancer cases unrelated to AIDS: Is it real? J Clin Oncol; 2009 May 20;27(15_suppl):e17535

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e17535 Background: Juvenile Cancer (JC) involves patients between 18 and 29 years old (adult pt less than 30 yo) and can be or not associated to AIDS.
  • The non-AIDS JC pt challenge the clinical oncologist in many ways: there are few preventive measures, avoiding delayed toxicities is mandatory (fertility, cognitive impairment) and there is a lack of evidence-based treatments for uncommon tumors.
  • The tumors were classified as expected (germinal, hematological, sarcoma, melanoma, CNS, thyroid, cervix, trophoblastic disease) or unexpected (breast, colon, ovarian, gastric, pancreatic, head and neck).
  • DIAGNOSIS: Expected tumors 269 pt (80%) (testicular tumors = 89 pt; lymphoma = 75 pt; sarcoma = 35 pt; melanoma = 17 pt; others = 53), Unexpected tumors 67 pt (20%) (gastrointestinal = 23 pt; breast cancer = 17 pt; ovarian = 13 pt; head and neck = 7 pt; others = 7 pt).
  • 2) Expected tumors represent 80% of the cases;.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963795.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Rogers PC, Lorenzi M, Broemeling A, Glickman V, Goddard K, Pritchard S, Sheps S, Siegel L, Spinelli J, McBride M: Childhood, adolescent, and young adult cancer survivors (CAYACS) research program of British Columbia: Data linkage: Results to date. J Clin Oncol; 2009 May 20;27(15_suppl):9555

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood, adolescent, and young adult cancer survivors (CAYACS) research program of British Columbia: Data linkage: Results to date.
  • Survivors were found to experience a drop in continuity of primary health care as they aged and transitioned into adult care.
  • Survivors were significantly more likely than their peers to receive special education (32.5% vs. 14.1%), most significantly among CNS survivors who received cranial irradiation.
  • Survivors of CNS tumors were at highest risk of poor health and educational outcomes measured.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963640.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Murray G, Jiménez L, Báez F, Colón-Castillo LE, Brau RH: Descriptive profile of surgically-confirmed adult central nervous system tumors in Puerto Rico. P R Health Sci J; 2009 Dec;28(4):317-28

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Descriptive profile of surgically-confirmed adult central nervous system tumors in Puerto Rico.
  • INTRODUCTION: Published studies regarding the incidence of central nervous system (CNS) tumors in Puerto Rico (PR) are exceedingly rare.
  • The general understanding is that the incidence of these tumors in Puerto Rico is similar to the one found in the United States of America (USA).
  • The objective of this study is to describe the specific profile of all the CNS tumors that are surgically intervened in Puerto Rico, through the creation of a database.
  • METHODS: A retrospective analysis of all the surgical procedures from January 1, 2002 to May 31, 2006 for adult CNS tumors in Puerto Rico was performed.
  • The information was organized to form a database of all the CNS neoplasms.
  • RESULTS: A total of 1,018 procedures for CNS tumors were performed on 1,005 patients.
  • The incidence rate of surgically intervened CNS tumors in Puerto Rico is 6 per 100,000 people.
  • CNS tumors were more common in women than in men (58% vs. 42%), respectively.
  • CONCLUSIONS: Our results reflect a unique histopathological distribution of operated CNS tumors in Puerto Rico.
  • In this series, primary tumors are more common than metastatic tumors.
  • Benign histological tumors were more frequent than more malignant variants.
  • Although this study reflects only the histologically diagnosed tumors, it is headway towards diagnosing the incidence of all CNS tumors in Puerto Rico.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Central Nervous System Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Puerto Rico. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999240.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Puerto Rico
  •  go-up   go-down


15. Tatsumi M, Miller JH, Wahl RL: 18F-FDG PET/CT in evaluating non-CNS pediatric malignancies. J Nucl Med; 2007 Dec;48(12):1923-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG PET/CT in evaluating non-CNS pediatric malignancies.
  • We reviewed our experience of (18)F-FDG PET/CT in noncentral nervous system (CNS) pediatric malignancies and evaluated if PET/CT provided additional information to conventional imaging (CI) examinations to determine the efficacy of this new imaging modality in the clinical setting.
  • METHODS: One-hundred fifty-one consecutive FDG PET/CT examinations in 55 pediatric patients with non-CNS malignant tumors were reviewed.
  • PET/CT was demonstrated to be an accurate imaging modality in evaluating pediatric patients with non-CNS malignancies.
  • [MeSH-major] Fluorodeoxyglucose F18. Neoplasms / radiography. Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Magnetic Resonance Imaging. Male. Retrospective Studies


16. da Silva NS, Cappellano AM, Diez B, Cavalheiro S, Gardner S, Wisoff J, Kellie S, Parker R, Garvin J, Finlay J: Primary chemotherapy for intracranial germ cell tumors: results of the third international CNS germ cell tumor study. Pediatr Blood Cancer; 2010 Mar;54(3):377-83
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary chemotherapy for intracranial germ cell tumors: results of the third international CNS germ cell tumor study.
  • BACKGROUND: The treatment of central nervous system (CNS) germ cell tumors (GCT) remains controversial.
  • METHODS: Between January 2001 and December 2004 newly diagnosed patients with CNS GCT were treated with one of two risk-tailored chemotherapy regimens.
  • Twenty-five patients aged 4 months to 24.5 years were stratified: Regimen A consisted of 4-6 cycles of carboplatin/etoposide alternating with cyclophosphamide/etoposide for low risk (LR) localized germinoma with normal cerebrospinal fluid (CSF) and serum tumor markers.
  • Our results indicate that, at the present time, standard treatment for CNS GCT continues to include irradiation either alone or combined with chemotherapy for pure germinomas and with chemotherapy for those with MMGCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Neoplasms, Germ Cell and Embryonal / drug therapy
  • [MeSH-minor] Adolescent. Adult. Carboplatin / administration & dosage. Carboplatin / adverse effects. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Infant. Male. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • (PMID = 20063410.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


17. Grimm S, Chamberlain MC: Adult primary spinal cord tumors. Expert Rev Neurother; 2009 Oct;9(10):1487-95

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult primary spinal cord tumors.
  • Primary spinal cord tumors represent 2-4% of all neoplasms of the CNS.
  • Primary spinal cord tumors are anatomically separable into two broad categories: intradural intramedullary and intradural extramedullary.
  • Intramedullary tumors are comprised predominantly of gliomas (infiltrative astrocytomas and ependymomas).
  • Resective surgery can usually be accomplished with spinal ependymomas owing to separation of tumor from spinal cord and, when complete, require no further therapy.
  • Intradural extramedullary tumors are either peripheral nerve sheath tumors (neurofibromas or schwanommas) or meningiomas.
  • Chemotherapy is administered for recurrent primary spinal cord tumors without other options, that is, reoperation or re-irradiation.
  • Problematic, however, is the lack of clinical trials in general for these CNS tumors and for spinal cord tumors in particular.
  • Consequently, treatment is similar to that for intracranial tumors with a similar histology.
  • Early recognition of the signs and symptoms of primary spinal cord tumors allows for early treatment, potentially minimizes neurologic morbidity and improves outcome.
  • Primary treatment is surgery in essentially all spinal cord tumors, and predictors of outcome include preoperative functional status, histological grade of tumor and extent of surgical resection.
  • [MeSH-major] Spinal Cord Neoplasms / classification. Spinal Cord Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Neurosurgical Procedures. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19831838.001).
  • [ISSN] 1744-8360
  • [Journal-full-title] Expert review of neurotherapeutics
  • [ISO-abbreviation] Expert Rev Neurother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 82
  •  go-up   go-down


18. Khatua S, Dhall G, O'Neil S, Jubran R, Villablanca JG, Marachelian A, Nastia A, Lavey R, Olch AJ, Gonzalez I, Gilles F, Nelson M, Panigrahy A, McComb G, Krieger M, Fan J, Sposto R, Finlay JL: Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation. Pediatr Blood Cancer; 2010 Jul 15;55(1):42-6
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation.
  • BACKGROUND: The purpose of this study was to evaluate a reduced irradiation dose strategy for newly diagnosed primary central nervous system (CNS) germinomas.
  • Initial tumor markers for beta-human chorionic gonadotrophin (HCGbeta) and alpha-fetoprotein (AFP) were evaluated in serum and lumbar cerebrospinal fluid (CSF).
  • RESULTS: Eighteen of 20 patients are without evidence of residual or recurrent tumor.
  • Both relapsing patients were subsequently determined to harbor malignant non-germinomatous germ cell tumor (NGGCT).
  • CONCLUSION: Chemotherapy followed by reduced dose whole ventricular and local boost irradiation appears to be effective in patients with localized pure CNS germinoma with evidence of preservation of neurocognitive function.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Central Nervous System Neoplasms / therapy. Germinoma / therapy. Neoplasms, Germ Cell and Embryonal / therapy
  • [MeSH-minor] Adolescent. Adult. Carboplatin / adverse effects. Carboplatin / therapeutic use. Child. Child, Preschool. Chorionic Gonadotropin, beta Subunit, Human / blood. Combined Modality Therapy. Dose-Response Relationship, Radiation. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Retrospective Studies. Young Adult. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20222020.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


19. Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, Goss B, Ford J: CNS germ cell tumors: pattern of failure and effects of radiation volume. J Med Assoc Thai; 2006 Apr;89(4):415-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS germ cell tumors: pattern of failure and effects of radiation volume.
  • This retrospective study was conducted to evaluate local control and overall survival after radiotherapy for patients with intracranial germ cell tumors and to investigate the influence of irradiated field on treatment outcome.
  • Thirty-two patients with surgically confirmed or suspected primary intracranial germ cell tumors (GCT) treated at the Division of Therapeutic Radiology and Oncology, Chiang Mai University, Chiang Mai, Thailand between January 1988 and December 1999 were reviewed Seven patients were not included in the analysis of treatment outcome and survival due to incompleteness of radiation treatment or death before the end of treatment.
  • Patients were irradiated to the primary tumor with an adequate margin in 7 patients, to the whole brain with a cone down boost in 8 patients.
  • [MeSH-major] Central Nervous System Neoplasms / radiotherapy. Neoplasm Recurrence, Local. Neoplasms, Germ Cell and Embryonal / radiotherapy. Treatment Outcome
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Middle Aged. Pinealoma / mortality. Pinealoma / radiotherapy. Retrospective Studies. Risk Factors. Survival Rate. Thailand / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16696383.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


20. Hendrickson KC, Rimar J: Patterns of hospital resource utilization of children with leukemia and CNS tumors: a comparison of children who survive and those who die within 3 years of diagnosis. Nurs Econ; 2009 Jan-Feb;27(1):35-44
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of hospital resource utilization of children with leukemia and CNS tumors: a comparison of children who survive and those who die within 3 years of diagnosis.
  • The two childhood cancers most commonly requiring hospitalization are leukemia and tumors of the central nervous system (CNS tumors).
  • [MeSH-major] Central Nervous System Neoplasms / economics. Health Care Costs. Hospitalization / statistics & numerical data. Leukemia / economics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Intensive Care Units, Pediatric / utilization. Length of Stay. Male. New England. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19331311.001).
  • [ISSN] 0746-1739
  • [Journal-full-title] Nursing economic$
  • [ISO-abbreviation] Nurs Econ
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Ahuja G, Cuellar S, Choudhry I, Setty S, Yao M, Villano JL: Complete response of CNS-involved olfactory neuroendocrine tumor using multimodal therapy. Onkologie; 2008 Mar;31(3):119-21
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response of CNS-involved olfactory neuroendocrine tumor using multimodal therapy.
  • INTRODUCTION: Locally advanced tumors in the olfactory area commonly have central nervous system (CNS) involvement and are often incurable.
  • CASE REPORT: We report the treatment of a 25-year-old male patient who presented with a large, neuroendocrine tumor arising from the ethmoid complex.
  • An endoscopic nasal biopsy demonstrated a poorly differentiated neuroendocrine tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / therapy. Ethmoid Bone / pathology. Neuroendocrine Tumors / therapy. Radiotherapy, Adjuvant. Skull Neoplasms / therapy
  • [MeSH-minor] Adult. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Humans. Male. Organization and Administration

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18322415.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


22. Gläsker S, Klingler JH, Müller K, Würtenberger C, Hader C, Zentner J, Neumann HP, Velthoven VV: Essentials and pitfalls in the treatment of CNS hemangioblastomas and von Hippel-Lindau disease. Cent Eur Neurosurg; 2010 May;71(2):80-7
MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Essentials and pitfalls in the treatment of CNS hemangioblastomas and von Hippel-Lindau disease.
  • Hemangioblastomas are rare CNS tumors, which are mostly located in the posterior fossa or spinal cord and occasionally in spinal nerves.
  • They can occur sporadically or as a component tumor of von Hippel-Lindau (VHL) disease, an autosomal dominant tumor syndrome.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / surgery. Hemangioblastoma / pathology. Hemangioblastoma / surgery. Neurosurgical Procedures / methods. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / surgery. von Hippel-Lindau Disease / pathology. von Hippel-Lindau Disease / surgery
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Georg Thieme Verlag KG Stuttgart . New York.
  • (PMID = 20229452.001).
  • [ISSN] 1868-4912
  • [Journal-full-title] Central European neurosurgery
  • [ISO-abbreviation] Cent Eur Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Engelhard HH, Corsten LA: Leptomeningeal metastasis of primary central nervous system (CNS) neoplasms. Cancer Treat Res; 2005;125:71-85
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal metastasis of primary central nervous system (CNS) neoplasms.
  • Leptomeningeal dissemination of primary CNS tumors varies widely by histologic subtype.
  • In certain tumors including medulloblastoma, ependymoma, germ cell tumors, and primary CNS lymphoma, seeding of the cerebrospinal fluid space is a critical factor in determining stage, prognosis and appropriate therapy.
  • Other tumor types, such as glioma, may have radiographic evidence of leptomeningeal metastases without clear impact on prognosis or therapy.
  • [MeSH-major] Brain Neoplasms / pathology. Central Nervous System Neoplasms / pathology. Meningeal Neoplasms / secondary
  • [MeSH-minor] Adult. Child. Humans. Incidence

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16211884.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 86
  •  go-up   go-down


24. Zhu Y, Harada T, Liu L, Lush ME, Guignard F, Harada C, Burns DK, Bajenaru ML, Gutmann DH, Parada LF: Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development; 2005 Dec;132(24):5577-88
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.
  • The gene responsible for neurofibromatosis type 1 (NF1) encodes a tumor suppressor that functions as a negative regulator of the Ras proto-oncogene.
  • Individuals with germline mutations in NF1 are predisposed to the development of benign and malignant tumors of the peripheral and central nervous system (CNS).
  • Children with this disease suffer a high incidence of optic gliomas, a benign but potentially debilitating tumor of the optic nerve; and an increased incidence of malignant astrocytoma, reactive astrogliosis and intellectual deficits.
  • In the present study, we have sought insight into the molecular and cellular basis of NF1-associated CNS pathologies.
  • We show that mice genetically engineered to lack NF1 in CNS exhibit a variety of defects in glial cells.
  • Primary among these is a developmental defect resulting in global reactive astrogliosis in the adult brain and increased proliferation of glial progenitor cells leading to enlarged optic nerves.
  • These data point to hyperproliferative glial progenitors as the source of the optic tumors and provide a genetic model for NF1-associated astrogliosis and optic glioma.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuropathol Appl Neurobiol. 2000 Aug;26(4):361-7 [10931370.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Sep;59(9):759-67 [11005256.001]
  • [Cites] J Neurosci. 2005 Jun 8;25(23):5584-94 [15944386.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7773-9 [15520182.001]
  • [Cites] Am J Med Genet. 1999 Mar 26;89(1):38-44 [10469435.001]
  • [Cites] Oncogene. 1999 Aug 5;18(31):4450-9 [10442636.001]
  • [Cites] Neuron. 2000 May;26(2):533-41 [10839371.001]
  • [Cites] Science. 2000 Feb 25;287(5457):1433-8 [10688783.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] Nat Rev Cancer. 2005 Jul;5(7):557-64 [16069817.001]
  • [Cites] Development. 2000 Dec;127(24):5253-63 [11076748.001]
  • [Cites] Neuron. 2000 Oct;28(1):69-80 [11086984.001]
  • [Cites] Nature. 2001 Feb 8;409(6821):714-20 [11217860.001]
  • [Cites] Nat Rev Genet. 2001 Feb;2(2):120-9 [11253051.001]
  • [Cites] Nat Rev Neurosci. 2001 Apr;2(4):287-93 [11283751.001]
  • [Cites] Neurology. 2001 Apr 10;56(7):885-90 [11294925.001]
  • [Cites] Genes Dev. 2001 Apr 1;15(7):859-76 [11297510.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):917-20 [11556548.001]
  • [Cites] Genesis. 2001 Oct;31(2):85-94 [11668683.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):112-7 [11689956.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2085-91 [11929829.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] Mol Cell Biol. 2002 Jul;22(14):5100-13 [12077339.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):616-26 [12154354.001]
  • [Cites] J Neurosci. 2002 Nov 1;22(21):9228-36 [12417648.001]
  • [Cites] Neuron. 2003 Mar 6;37(5):751-64 [12628166.001]
  • [Cites] J Neurosci. 2003 Aug 6;23(18):7207-17 [12904481.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8573-7 [14695164.001]
  • [Cites] Neuron. 2004 Mar 25;41(6):881-90 [15046721.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] Cell. 1990 Nov 16;63(4):835-41 [2121369.001]
  • [Cites] Cell. 1990 Nov 16;63(4):851-9 [2121371.001]
  • [Cites] Neuron. 1992 Mar;8(3):415-28 [1550670.001]
  • [Cites] Dev Dyn. 1992 Nov;195(3):216-26 [1301085.001]
  • [Cites] Dev Biol. 1994 Feb;161(2):538-51 [8314000.001]
  • [Cites] Neuron. 1994 Apr;12(4):895-908 [8161459.001]
  • [Cites] Curr Biol. 1994 Jan 1;4(1):1-7 [7922305.001]
  • [Cites] Genes Dev. 1994 May 1;8(9):1019-29 [7926784.001]
  • [Cites] Development. 1994 Sep;120(9):2637-49 [7956838.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jul;54(4):588-600 [7602332.001]
  • [Cites] J Cell Biol. 1995 Oct;131(2):453-64 [7593171.001]
  • [Cites] Development. 1995 Nov;121(11):3583-92 [8582272.001]
  • [Cites] Mol Cell Biol. 1997 Feb;17(2):862-72 [9001241.001]
  • [Cites] Ann Neurol. 1997 Feb;41(2):143-9 [9029062.001]
  • [Cites] Trends Neurosci. 1997 Dec;20(12):570-7 [9416670.001]
  • [Cites] Cell. 1998 Sep 18;94(6):703-14 [9753318.001]
  • [Cites] Brain Res. 1999 Jan 16;816(1):111-23 [9878702.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] J Neurosci. 1999 Feb 1;19(3):1049-61 [9920668.001]
  • (PMID = 16314489.001).
  • [ISSN] 0950-1991
  • [Journal-full-title] Development (Cambridge, England)
  • [ISO-abbreviation] Development
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS052606-01; United States / NINDS NIH HHS / NS / P50 NS052606; United States / NINDS NIH HHS / NS / P50 NS052606-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neurofibromin 1
  • [Other-IDs] NLM/ NIHMS149022; NLM/ PMC2760350
  •  go-up   go-down


25. Teng FY, Tang BL: No go for brain tumors? J Mol Neurosci; 2005;25(1):1-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No go for brain tumors?
  • The Nogo gene and its products are well known as adult central nervous system (CNS) myelin inhibitors of neuronal regeneration.
  • We review here experimental findings that might link Nogo to CNS malignancy.
  • On the other hand, extracellular domains of Nogo might inhibit the migration and invasion of CNS tumors.
  • Depending on the physiological context, Nogo isoforms might therefore be antitumorigenic or have tumor-suppressing activities.
  • [MeSH-major] Antineoplastic Agents / metabolism. Brain Neoplasms / genetics. Growth Inhibitors. Myelin Proteins
  • [MeSH-minor] Central Nervous System / pathology. Central Nervous System / physiology. Humans. Protein Isoforms / genetics. Protein Isoforms / metabolism. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15781961.001).
  • [ISSN] 0895-8696
  • [Journal-full-title] Journal of molecular neuroscience : MN
  • [ISO-abbreviation] J. Mol. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Growth Inhibitors; 0 / Myelin Proteins; 0 / Nogo protein; 0 / Protein Isoforms; 0 / Proto-Oncogene Proteins
  • [Number-of-references] 32
  •  go-up   go-down


26. Santagata S, Hornick JL, Ligon KL: Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG. Am J Surg Pathol; 2006 Dec;30(12):1613-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG.
  • Expression of NANOG has been detected in fetal germ cells and in gonadal germ cell tumors.
  • To assess the diagnostic utility of NANOG in central nervous system (CNS) germ cell tumors, we analyzed its expression by immunohistochemistry in a series of 12 CNS germinomas and compared its expression with other stem cell markers.
  • Strong nuclear expression of NANOG was demonstrated in >90% of the tumor cells in all cases.
  • NANOG was not detected in tumor types frequently considered in the differential diagnosis of CNS germinoma: pineoblastoma, primitive neuroectodermal tumors, medulloblastoma, lymphoma, pituitary adenoma, atypical teratoid/rhabdoid tumor, Langerhans cell histiocytosis, and gliomas.
  • These findings demonstrate that NANOG is a sensitive and specific marker of CNS germinoma.
  • Compared with other currently used markers, NANOG may have superior diagnostic characteristics and can facilitate identification of germinomas in minute surgical biopsies commonly obtained from these tumors.
  • These findings also suggest a potential biologic role for NANOG in maintenance of CNS germinoma.
  • [MeSH-major] Brain Neoplasms / metabolism. DNA-Binding Proteins / metabolism. Germinoma / metabolism. Homeodomain Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Alkaline Phosphatase / metabolism. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Child. HMGB Proteins / metabolism. Humans. Isoenzymes / metabolism. Octamer Transcription Factor-3 / metabolism. SOXB1 Transcription Factors. Transcription Factors / metabolism

  • Genetic Alliance. consumer health - Germinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122519.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS047213
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / HMGB Proteins; 0 / Homeodomain Proteins; 0 / Isoenzymes; 0 / NANOG protein, human; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors; 0 / Transcription Factors; 0 / germ-cell AP isoenzyme; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


27. Kieran MW, Walker D, Frappaz D, Prados M: Brain tumors: from childhood through adolescence into adulthood. J Clin Oncol; 2010 Nov 10;28(32):4783-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumors: from childhood through adolescence into adulthood.
  • Clinical care is currently divided into adult or pediatric care; adolescent patients require specific expertise that most clinical practices do not have.
  • When illness coincides with the adolescent transition, the health system is severely challenged.
  • Health systems historically have varied widely in the age they choose for allocating an individual to the adult model of health care.
  • Tumors of the CNS complicate the difficult adjustments required in adolescents and young adults by virtue of their morbidity, complex treatment, and prognosis.
  • Some brain tumors are unique to children, some occur predominantly in adults, and others peak in adolescence.
  • Delays in the diagnosis of brain tumors can occur at any age but are particularly common in adolescence because of difficulties of accessing health systems, the difficulties of discriminating pathologic from typical adolescent behavioral characteristics, and changing endocrine function.
  • This article will discuss the changing brain tumor profile of children, adolescents, and adults, with a focus on our limited understanding of the adolescent/young adult transition period.
  • [MeSH-major] Brain Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adolescent Medicine. Adult. Brain / growth & development. Child. Continuity of Patient Care. Glioma / diagnosis. Glioma / therapy. Humans. Medulloblastoma / diagnosis. Medulloblastoma / therapy. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20458039.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


28. Rodríguez D, Cheung MC, Housri N, Quinones-Hinojosa A, Camphausen K, Koniaris LG: Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973-2005). J Surg Res; 2009 Oct;156(2):340-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973-2005).
  • BACKGROUND: Determine the role of surgery and radiation therapy for patients with malignant CNS ependymomas.
  • Univariate analysis demonstrated that age, gender, ethnicity, primary tumor site, WHO grade and surgical resection were significant predictors of improved survival for ependymoma patients.
  • Multivariate analysis identified that a WHO grade III tumor, male gender, patient age, intracranial tumor locations and failure to undergo surgical resection were independent predictors of poorer outcomes.
  • For partially resected tumors, radiation therapy provides significant survival benefit.
  • [MeSH-major] Central Nervous System Neoplasms / radiotherapy. Central Nervous System Neoplasms / surgery. Ependymoma / radiotherapy. Ependymoma / surgery
  • [MeSH-minor] Adult. Female. Humans. Male. SEER Program. Treatment Outcome. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19577759.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Chu LC, Eberhart CG, Grossman SA, Herman JG: Epigenetic silencing of multiple genes in primary CNS lymphoma. Int J Cancer; 2006 Nov 15;119(10):2487-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic silencing of multiple genes in primary CNS lymphoma.
  • Primary central nervous system lymphoma (PCNSL) is an increasingly common tumor that has not been extensively examined for changes in promoter region methylation.
  • We examined 14 tumor suppressor genes in 25 cases of PCNSL using methylation-specific PCR.
  • Methylation of DAPK, p16(INK) (4a) or MGMT was found in 96% of the tumors, suggesting simple marker strategies to detect circulating methylated DNA in serum that might facilitate early tumor detection.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Epigenesis, Genetic. Gene Silencing. Genes, Tumor Suppressor. Lymphoma / genetics
  • [MeSH-minor] Adult. Aged. DNA Methylation. DNA, Neoplasm / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Promoter Regions, Genetic


30. Galimi F, Summers RG, van Praag H, Verma IM, Gage FH: A role for bone marrow-derived cells in the vasculature of noninjured CNS. Blood; 2005 Mar 15;105(6):2400-2
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A role for bone marrow-derived cells in the vasculature of noninjured CNS.
  • Bone marrow-derived endothelial progenitor cells are thought to generate endothelial cells in many tissues, including myocardium, muscle, and certain tumors.
  • In the central nervous system (CNS), however, the possible role of bone marrow-derived angiocompetent cells remains unclear.
  • Using hematopoietic chimeras stably expressing green fluorescent protein (GFP) in bone marrow-derived tissues, we found large numbers of hematopoietic cells closely associated with vessels in the CNS.
  • Bone marrow-derived, vasculature-associated cells in the noninjured adult CNS are distinct from endothelial cells, but play an active role in vascular structures.
  • [MeSH-major] Bone Marrow Cells / physiology. Central Nervous System / physiology. Endothelial Cells / physiology. Neovascularization, Physiologic. Stem Cell Transplantation. Transplantation Chimera / physiology
  • [MeSH-minor] Animals. Mice. Mice, Transgenic. Microglia / cytology. Microglia / physiology. Monocytes / cytology. Monocytes / physiology. Muscle, Skeletal / blood supply. Muscle, Skeletal / cytology. Muscle, Skeletal / metabolism. Myocardium / cytology. Myocardium / metabolism. Neoplasms / blood supply. Neoplasms / metabolism. Neovascularization, Pathologic / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15572598.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


31. Vrkljan M, Matovinović M, Marić A, Bekić M, Zah T, Resetić J, Vizner B, Pećina HI, Cerina V, Gnjidić Z: Incidence of pituitary tumors in the human population of Croatia. Coll Antropol; 2006 Mar;30(1):157-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of pituitary tumors in the human population of Croatia.
  • Pituitary tumors are rare tumors (less then 10%) of the central nervous system (CNS), which malignicity depends on their localization, meanwhile, their biological nature is benign.
  • The diameter they have is mostly less then 10 mm (microadenomas), but sometimes could be 10 mm (macroadenomas) to 5 cm and more and then are usually nonfunctional (about 20% of all pituitary tumors).
  • In the Center for Clinical Neuroendocrinology and Pituitary Diseases, in the last working 10 years, there were treated and examined 504 patients from Croatia, all with pituitary tumors: 182 patients with prolactinomas, 137 with acromegaly, 70 with Morbus Cushing (Mb.
  • Cushing), and 115 patients with nonfunctional pituitary tumors.
  • In our analysis we haven't found difference in incidence of tumors between Mediterranean and continental region.
  • [MeSH-major] Pituitary Neoplasms / epidemiology. Prolactinoma / epidemiology
  • [MeSH-minor] Acromegaly / epidemiology. Adolescent. Adult. Child. Croatia / epidemiology. Female. Humans. Incidence. Male. Pituitary ACTH Hypersecretion / epidemiology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16617591.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


32. Erickson ML, Johnson R, Bannykh SI, de Lotbiniere A, Kim JH: Malignant rhabdoid tumor in a pregnant adult female: literature review of central nervous system rhabdoid tumors. J Neurooncol; 2005 Sep;74(3):311-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant rhabdoid tumor in a pregnant adult female: literature review of central nervous system rhabdoid tumors.
  • Rhabdoid tumors of the central nervous system are uncommon, aggressive childhood malignancies.
  • The 13 described adult cases comprise both primary CNS tumors and malignant transformation of previously existing gliomas, meningiomas, and astrocytomas.
  • Central nervous system rhabdoid lesions of adults have been diagnosed as primary malignant rhabdoid tumors, atypical teratoid/rhabdoid tumors, and more recently, rhabdoid glioblastomas.
  • Pathologic evaluation revealed histology, electron microscopy and immunohistochemistry consistent with the diagnosis of malignant rhabdoid tumor.
  • FISH studies were negative for the INI-1 genetic mutations and chromosome 22q deletion associated with childhood atypical rhabdoid/rhabdoid tumor in 75% of cases.
  • We briefly describe the characteristics and current understanding of rhabdoid tumors, and review the literature comparing the 12 other cases of central nervous system rhabdoid tumors in adults.
  • Furthermore, we consider and discuss the implications of this case being the second presentation of MRT during pregnancy in only six adult female patients.
  • [MeSH-major] Brain Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology. Rhabdoid Tumor / pathology
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Microscopy, Electron, Transmission. Pregnancy


33. Badruddoja MA, Keir ST, King I, Zeidner J, Vredenburgh JJ, Muhlbaier LH, Bigner DD, Friedman HS: Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice. Neuro Oncol; 2007 Jul;9(3):240-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice.
  • The current study was designed to assess the activity of VNP40101M administered at a dose of 18 mg/kg daily for five days against a panel of human adult and pediatric CNS tumors growing subcutaneously or intracranially in athymic nude mice.
  • The results demonstrated statistically significant (p < 0.05) growth delays of 15.0, 8.3, 51.0, 60+, 60+, and 60+ days in subcutaneous xenografts derived from childhood glioblastoma multiforme (D-456 MG), childhood ependymoma (D-528 EP and D-612 EP), childhood medulloblastoma (D-425 MED), and adult malignant glioma (D-245 MG and D-54 MG), respectively, with corresponding tumor regressions in 10 of 10, 4 of 10, 8 of 10, 9 of 10, 9 of 10, and 10 of 10 treated mice, respectively.
  • Additional experiments conducted against subcutaneous D-245 MG xenografts by using reduced doses of 13.5 or 9.0 mg/kg daily for five days demonstrated tumor growth delays of 82.2 and 53.5 days, with corresponding tumor regressions in 8 of 9 and 9 of 10 treated mice, respectively (all values, p < 0.001), with one toxic death.
  • These findings suggest that VNP40101M is active in the treatment of a wide range of human central nervous system tumors and warrants translation to the clinic.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 1994;34(2):171-4 [8194169.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5368-72 [2164681.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2853-7 [7796412.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2933-6 [9230204.001]
  • [Cites] Invest New Drugs. 2005 Mar;23(2):123-35 [15744588.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Biochem Pharmacol. 2000 Feb 1;59(3):283-91 [10609557.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3033-8 [11306484.001]
  • [Cites] Int J Toxicol. 2002 Jan-Feb;21(1):23-38 [11936896.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Apr;53(4):288-95 [14685775.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2908-17 [15131024.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Neurosurgery. 1979 Apr;4(4):308-14 [450229.001]
  • [Cites] Cancer Res. 1988 Aug 1;48(15):4189-95 [3390813.001]
  • [Cites] J Neurooncol. 1994;20(2):111-20 [7807189.001]
  • (PMID = 17522334.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P50 NS020023; United States / NINDS NIH HHS / NS / 5P50-NS20023-23
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydrazines; 0 / Prodrugs; 0 / Sulfonamides; 14J2G0U3NQ / laromustine
  • [Other-IDs] NLM/ PMC1907418
  •  go-up   go-down


34. Kabashi S, Muçaj S, Ahmetgjekaj I, Gashi S, Fazliu I, Dreshaj S, Shala N: Radiological imaging detection of tumors localized in fossa cranii posterior. Med Arh; 2008;62(5-6):271-4
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiological imaging detection of tumors localized in fossa cranii posterior.
  • Intracranial tumors are characterized by a variety imaging aspects and their detection is always a challenge.
  • Clinical application of Magnetic Resonance Imaging (MRI) and Computerized Tomography has provided an earlier detection and treatment of many CNS pathologies.
  • The aim of this study is to estimate the role of CT and MRI in the determination of posterior fossa tumors.
  • RESULTS: During period 2000-2005 in UCCK-Prishtina, 368 patients were diagnosed with intracranial tumors.
  • Fifty-nine of them were found to have tumor localized in fossa crani posterior (FCP) without any significant difference between genders (50.8% female vs. 49.2% male, chi2 test=0.02 p=0.896).
  • The average age of patients with FCP tumors was 33.1 (SD +/- 22.5, rank 1-70).
  • Tumor types that more often were found in young's individuals were: Astrocytomas with a peak incidence in teenagers (average age was 12-year-old SD +/- 7.5, rank 3-23), next was Medulloblastomas (average age was 11-years-old, SD +/- 2.9, rank 6-16 years) and ependymomas (average age was 6.8-years-old, SD +/- 4.6, rank 1-12).
  • Patients with osseous tumors are characterized by older age than median (61.0, SD +/- 4.2, rank 58-64), then metastases (53.0, SD +/- 5.3, rank 45-60) and meningiomas (50.8, SD +/- 7.7, rank 38-63).
  • CONCLUSION: Comparing with other countries, for some types of FCP tumors, lower morbidity is shown in Kosova, with mean incidence 0.41/100,000.
  • The most frequent tumors in children were medulloblastomas, brainstem gliomas, astrocytomas and ependymomas whereas meningiomas and metastasis were most often found in adults.
  • For FCP tumors detection, MRI had 100% sensitivity, specificity and predictive positive value, whereas brain CT was characterized by 95% sensitivity, 90.4 % specificity and 91% predictive positive value.
  • [MeSH-major] Infratentorial Neoplasms / diagnosis. Magnetic Resonance Imaging. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19469268.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


35. Ligon KL, Fancy SP, Franklin RJ, Rowitch DH: Olig gene function in CNS development and disease. Glia; 2006 Jul;54(1):1-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olig gene function in CNS development and disease.
  • Olig1 and Olig2 encode basic helix-loop-helix (bHLH) transcription factors that are expressed in both the developing and mature vertebrate central nervous system.
  • Recent studies, however, reveal that in the fetal dorsal spinal cord and neural progenitor cells of the adult brain, Olig expression continues to mark, and may regulate, the formation of oligodendroglia.
  • Studies of Olig expression in human brain tumors and repair of demyelinating lesions suggest the possibility of additional functions in a variety of neurological diseases.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / metabolism. Cell Differentiation / genetics. Central Nervous System / embryology. Gene Expression Regulation, Developmental / genetics. Nerve Tissue Proteins / metabolism. Oligodendroglia / metabolism. Stem Cells / metabolism
  • [MeSH-minor] Animals. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Brain Neoplasms / therapy. Cell Lineage / genetics. Demyelinating Diseases / genetics. Demyelinating Diseases / metabolism. Demyelinating Diseases / therapy. Humans

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16652341.001).
  • [ISSN] 0894-1491
  • [Journal-full-title] Glia
  • [ISO-abbreviation] Glia
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Nerve Tissue Proteins; 0 / OLIG1 protein, human
  • [Number-of-references] 106
  •  go-up   go-down


36. Kreisl TN, Toothaker T, Karimi S, DeAngelis LM: Ischemic stroke in patients with primary brain tumors. Neurology; 2008 Jun 10;70(24):2314-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ischemic stroke in patients with primary brain tumors.
  • BACKGROUND: Primary brain tumor patients are at increased risk for stroke from disease and treatment-specific mechanisms.
  • METHODS: We conducted a retrospective review of patients with primary brain tumors diagnosed with MRI-confirmed ischemic stroke between 1996 and 2006.
  • The most common brain tumors were gliomas, 60%; meningiomas, 25%; and primary CNS lymphoma, 6%.
  • CONCLUSIONS: Treatment complications from surgery and radiotherapy account for the majority of ischemic strokes in patients with primary brain tumors.
  • [MeSH-major] Brain Ischemia / etiology. Brain Neoplasms / complications. Stroke / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neurosurgical Procedures / adverse effects. Radiotherapy / adverse effects. Retrospective Studies. Risk Factors. Survival Rate


37. De Sio L, Milano GM, Castellano A, Jenkner A, Fidani P, Dominici C, Donfrancesco A: Temozolomide in resistant or relapsed pediatric solid tumors. Pediatr Blood Cancer; 2006 Jul;47(1):30-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide in resistant or relapsed pediatric solid tumors.
  • PURPOSE: We report the off-label study aimed at investigating the use of temozolomide (TMZ) as single agent in relapsed or resistant pediatric solid tumors.
  • PATIENTS AND METHODS: Fifty two patients, median age 127.6 months, with resistant or relapsed solid tumors were enrolled.
  • Tumor types were: neuroblastoma (NB; n = 17), medulloblastoma (MB; 8), brain stem glioma (BSG; 8), extraosseous Ewing's sarcoma/peripheral neuroectodermal tumor (EOES; 4), Ewing's sarcoma (ES; 4), anaplastic astrocytoma (AA; 3), rhabdomyosarcoma (RMS; 2), ependymoma (EP; 2), cerebral primitive neuroectodermal tumor (cPNET; 2), hepatocarcinoma (HC; 1), and osteosarcoma (OS; 1).
  • CONCLUSION: Oral TMZ was well tolerated in children with resistant or relapsed solid tumors and showed activity in NB and CNS tumours refractory to standard chemotherapy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Drug Resistance, Neoplasm. Neoplasm Recurrence, Local / drug therapy. Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Humans. Male. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • [ErratumIn] Pediatr Blood Cancer. 2006 Oct 15;47(5):647-8
  • (PMID = 16047361.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


38. Wernicke AG, Sherr DL, Schwartz TH, Pannullo SC, Stieg PE, Boockvar JA, Moliterno JA, Ivanidze J, Trichter S, Sabbas AM, Parashar B, Nori D: The role of dose escalation with intracavitary brachytherapy in the treatment of localized CNS malignancies: outcomes and toxicities of a prospective study. Brachytherapy; 2010 Jan-Mar;9(1):91-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of dose escalation with intracavitary brachytherapy in the treatment of localized CNS malignancies: outcomes and toxicities of a prospective study.
  • PURPOSE: This single-institution prospective study was designed to investigate the feasibility and safety of dose escalation with GliaSite (Proxima Therapeutics Inc., Alpharetta, GA) brachytherapy for the treatment of patients with newly diagnosed and recurrent central nervous system (CNS) tumors after neurosurgical resection.
  • METHODS AND MATERIALS: Ten adult consecutive patients with recurrent and newly diagnosed CNS malignancies underwent GliaSite brachytherapy after maximally safe neurosurgical resection between 2004 and 2007.
  • A commercial 3-D planning system was used for a detailed analysis of dosimetry.
  • CONCLUSIONS: Our data indicate that treatment with GliaSite balloon brachytherapy is feasible and safe, while rendering acceptable local control and minimal acute and long-term toxicities for newly diagnosed and recurrent CNS malignancies.
  • [MeSH-major] Brachytherapy / adverse effects. Brain Injuries / diagnosis. Brain Injuries / etiology. Brain Neoplasms / radiotherapy. Radiation Injuries / diagnosis. Radiation Injuries / etiology
  • [MeSH-minor] Adult. Aged. Dose Fractionation. Dose-Response Relationship, Radiation. Female. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
  • (PMID = 19850535.001).
  • [ISSN] 1873-1449
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Lasky JL 3rd, Choe M, Nakano I: Cancer stem cells in pediatric brain tumors. Curr Stem Cell Res Ther; 2009 Dec;4(4):298-305
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer stem cells in pediatric brain tumors.
  • Central nervous system (CNS) tumors remain the leading cause of death among pediatric neoplasms.
  • Although standard therapies cure many pediatric CNS tumors, the long-term cognitive and physical consequences of these therapies are devastating.
  • Although recent studies have focused on molecular mechanisms that underlie the initiation and progression of adult glioblastoma multiforme (GBM), these tumors differ phenotypically and at a molecular level from pediatric brain tumors.
  • Recent investigations have identified a stem cell population, termed "brain tumor stem cells" (BTSC) within the heterogeneous cell populations that comprise malignant brain tumors which may be partly responsible for the resistance to current therapies.
  • These have been identified in several pediatric tumors including medulloblastoma, ependymomas, and malignant gliomas.
  • By exploiting molecular differences present within these heterogeneous populations of brain tumor cells, we may be able to achieve specific eradication of BTSC and long-lasting remissions, while causing less toxicity to normal tissues.
  • In this review, we describe the issues surrounding the identification and characterization of BTSC, the molecular biology of BTSC for different pediatric brain tumors, and suggest future avenues for the development of treatments for this devastating disease.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology. Medulloblastoma / pathology. Neoplastic Stem Cells / pathology. Optic Nerve Glioma / pathology
  • [MeSH-minor] Adult Stem Cells / pathology. Biomarkers / metabolism. Cell Differentiation. Chemotherapy, Adjuvant. Child. Humans. Surgical Procedures, Operative


40. Hoffman S, Propp JM, McCarthy BJ: Temporal trends in incidence of primary brain tumors in the United States, 1985-1999. Neuro Oncol; 2006 Jan;8(1):27-37
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temporal trends in incidence of primary brain tumors in the United States, 1985-1999.
  • A number of reports have indicated an increasing incidence of primary brain tumors over the past few decades.
  • The purpose of this study was to describe incidence rate trends in a population-based series of newly diagnosed primary nonmalignant and malignant brain and other CNS tumors, contributing five additional years to previously published incidence trends.
  • Data for the years 1985 through 1999 from six collaborating state cancer registries of the Central Brain Tumor Registry of the United States were used to determine incidence trends in the broad age groups 0-19, 20-64, and >or=65 years, overall and for selected histologies.
  • Specific histologies that were increasing included anaplastic astrocytomas in individuals aged >or=65 years, microscopically confirmed gliomas in both adult age groups, and microscopically confirmed glioma, not otherwise specified (NOS), in children.
  • Increases that were not specific to any population subgroup were seen for oligodendrogliomas, ependymomas, meningiomas, and nerve sheath tumors.
  • Decreases were noted for astrocytoma, NOS, nonmicroscopically confirmed gliomas, and pituitary tumors.
  • However, increases in meningiomas and nerve sheath tumors deserve further attention.
  • [MeSH-major] Brain Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Child. Child, Preschool. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Registries

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroepidemiology. 2004 May-Jun;23(3):101-9 [15084778.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):1-11 [16443943.001]
  • [Cites] N Engl J Med. 1985 Oct 3;313(14):859-64 [3897866.001]
  • [Cites] AJR Am J Roentgenol. 1986 Sep;147(3):453-5 [3488645.001]
  • [Cites] J Natl Cancer Inst. 1990 Oct 17;82(20):1621-4 [2213902.001]
  • [Cites] Am J Ind Med. 1991;19(4):421-31 [2035544.001]
  • [Cites] CMAJ. 1991 Dec 15;145(12):1583-91 [1742695.001]
  • [Cites] J Natl Cancer Inst. 1991 Nov 20;83(22):1679-81 [1749021.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1300-6 [1739929.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 18;84(6):442-5 [1538422.001]
  • [Cites] Neurosurgery. 1992 Jul;31(1):78-82 [1641113.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):973-9 [7947107.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):330-7 [8001004.001]
  • [Cites] Ann Neurol. 1995 Jan;37(1):67-73 [7818260.001]
  • [Cites] Eur J Cancer. 1994;30A(10):1498-511 [7833109.001]
  • [Cites] IARC Sci Publ. 1994;(128):1-302 [7698823.001]
  • [Cites] Cancer. 1995 Nov 1;76(9):1634-42 [8635069.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):532-41 [8697401.001]
  • [Cites] Paediatr Perinat Epidemiol. 1996 Jul;10(3):319-38 [8822774.001]
  • [Cites] Int J Epidemiol. 1995 Dec;24(6):1078-85 [8824847.001]
  • [Cites] Stat Med. 2000 Feb 15;19(3):335-51 [10649300.001]
  • [Cites] Cancer. 2000 May 15;88(10):2342-9 [10820357.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):79-86 [11150357.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62 [11245209.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):141-51 [11465394.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):14-25 [11554386.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):257-9 [11958379.001]
  • [Cites] Neurology. 2002 Apr 23;58(8):1304-6 [11971109.001]
  • [Cites] Cancer. 2002 Jul 1;95(1):193-202 [12115333.001]
  • [Cites] J Neurooncol. 2002 Oct;60(1):61-9 [12416547.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Neuroepidemiology. 2003 Mar-Apr;22(2):124-9 [12629278.001]
  • [Cites] Int J Cancer. 2004 Jan 20;108(3):450-5 [14648713.001]
  • [Cites] Neuroepidemiology. 2004 Jan-Apr;23(1-2):85-93 [14739573.001]
  • [Cites] Am J Epidemiol. 2004 Feb 1;159(3):277-83 [14742288.001]
  • [Cites] Cancer. 1997 Apr 1;79(7):1381-93 [9083161.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1269-77 [9731733.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):648-9 [10203289.001]
  • [Cites] AIDS. 1999 Jan 14;13(1):103-8 [10207551.001]
  • [Cites] Cancer. 1999 May 1;85(9):2077-90 [10223251.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 2;91(11):973-4 [10359552.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1382-90 [10451443.001]
  • [Cites] Neurology. 1999 Sep 22;53(5):1141-3 [10496285.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2293-9 [15476282.001]
  • [Cites] Epidemiology. 2004 Nov;15(6):653-9 [15475713.001]
  • (PMID = 16443945.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1871920
  •  go-up   go-down


41. Barth RF, Kaur B: Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol; 2009 Sep;94(3):299-312
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas.
  • In this review we will describe eight commonly used rat brain tumor models and their application for the development of novel therapeutic and diagnostic modalities.
  • The C6, 9L and T9 gliomas were induced by repeated injections of methylnitrosourea (MNU) to adult rats.
  • The 9L gliosarcoma has been used widely and has provided important information relating to brain tumor biology and therapy.
  • Both of these tumors arose in Fischer rats and can be immunogenic in syngeneic hosts, a fact that must be taken into consideration when used in therapy studies, especially if survival is the endpoint.
  • The RG2 and F98 gliomas were both chemically induced by administering ethylnitrosourea (ENU) to pregnant rats, the progeny of which developed brain tumors that subsequently were propagated in vitro and cloned.
  • The CNS-1 glioma was induced by administering MNU to a Lewis rat.
  • This tumor has been used for a variety of studies to evaluate new therapeutic modalities.
  • The Avian Sarcoma Virus (ASV) induced tumors, and a continuous cell line derived from one of them designated RT-2, have been useful for studies in which de novo tumor induction is an important requirement.
  • These tumors also are immunogenic and this limits their usefulness for therapy studies.
  • [MeSH-major] Brain Neoplasms. Glioma
  • [MeSH-minor] Animals. Cell Line, Tumor / pathology. Disease Models, Animal. Gene Expression Regulation, Neoplastic. Mice. Rats

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2004 Nov;101(5):826-31 [15540922.001]
  • [Cites] Mol Ther. 2004 Dec;10(6):1071-84 [15564139.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8561-76 [15623640.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):341-50 [15671565.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2533-43 [15728459.001]
  • [Cites] Mol Cancer. 2005;4(1):12 [15762988.001]
  • [Cites] Brain Res Mol Brain Res. 2005 Apr 27;135(1-2):93-103 [15857672.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3475-84 [15867250.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3821-7 [15897582.001]
  • [Cites] J Neurooncol. 2005 May;72(3):209-15 [15937642.001]
  • [Cites] Brain Res. 2005 Jun 14;1047(1):56-64 [15893739.001]
  • [Cites] Am J Pathol. 2005 Aug;167(2):565-76 [16049340.001]
  • [Cites] J Neurosurg. 2005 Jan;102(1 Suppl):53-8 [16206734.001]
  • [Cites] Neurosurg Focus. 2005 Oct 15;19(4):E1 [16241103.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):603-11 [16338098.001]
  • [Cites] Mol Cancer Ther. 2006 Jan;5(1):52-9 [16432162.001]
  • [Cites] J Neurosurg. 2006 Jan;104(1):118-28 [16509155.001]
  • [Cites] J Neurooncol. 2007 Nov;85(2):133-48 [17874037.001]
  • [Cites] Neurochem Res. 2007 Dec;32(12):2235-42 [17701349.001]
  • [Cites] Free Radic Biol Med. 2008 Jan 1;44(1):63-72 [18045548.001]
  • [Cites] J Natl Cancer Inst. 2007 Dec 5;99(23):1768-81 [18042934.001]
  • [Cites] J Neurooncol. 2008 Jan;86(1):13-21 [17611717.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):883-91 [18245552.001]
  • [Cites] J Neurosurg. 2008 Feb;108(2):320-9 [18240929.001]
  • [Cites] Phys Med Biol. 2008 Feb 21;53(4):861-78 [18263945.001]
  • [Cites] Int J Immunopathol Pharmacol. 2008 Jan-Mar;21(1):227-31 [18336750.001]
  • [Cites] Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1977 Aug 15;89(3):273-95 [198983.001]
  • [Cites] J Neurosurg. 1979 Mar;50(3):298-304 [217977.001]
  • [Cites] Acta Neuropathol. 1980;51(1):23-31 [7435138.001]
  • [Cites] J Neurosurg. 1980 Dec;53(6):808-15 [7003068.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Sep;18(9):891-5 [6891332.001]
  • [Cites] J Neuropathol Exp Neurol. 1983 Mar;42(2):122-35 [6600780.001]
  • [Cites] J Neuropathol Exp Neurol. 1984 Jul;43(4):426-38 [6610726.001]
  • [Cites] Cancer Res. 1986 Oct;46(10):5276-81 [3019523.001]
  • [Cites] Cancer. 1987 Jan 15;59(2):266-70 [3026604.001]
  • [Cites] Ann Neurol. 1987 Sep;22(3):300-5 [3118762.001]
  • [Cites] Cancer Res. 1991 May 1;51(9):2373-8 [2015600.001]
  • [Cites] Cancer Res. 1991 May 1;51(9):2430-7 [2015604.001]
  • [Cites] J Clin Neurosci. 2008 May;15(5):545-51 [18378459.001]
  • [Cites] J Neurooncol. 2008 May;88(1):1-9 [18228115.001]
  • [Cites] Neuroimage. 2008 Apr 1;40(2):973-83 [18441552.001]
  • [Cites] J Neurosurg. 2008 May;108(5):972-8 [18447715.001]
  • [Cites] J Chemother. 2008 Apr;20(2):253-62 [18467254.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Jun;35(6):1192-203 [18264706.001]
  • [Cites] Toxicol Lett. 2008 Jun 10;179(1):29-33 [18485629.001]
  • [Cites] Cancer Res. 2008 Jul 15;68(14):5508-11 [18632599.001]
  • [Cites] Neuro Oncol. 2008 Jun;10(3):292-9 [18430796.001]
  • [Cites] J Cereb Blood Flow Metab. 2008 Aug;28(8):1431-9 [18414496.001]
  • [Cites] Brain Res. 2008 Aug 28;1227:198-206 [18602898.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2008 Jul-Aug;44(7):280-9 [18594936.001]
  • [Cites] J Neurooncol. 2008 Oct;90(1):19-24 [18594766.001]
  • [Cites] Eur J Pharm Biopharm. 2008 Sep;70(1):66-74 [18555675.001]
  • [Cites] Cancer Gene Ther. 2008 Oct;15(10):685-92 [18535615.001]
  • [Cites] Neurol Res. 2008 Jun;30(5):511-7 [18953742.001]
  • [Cites] NMR Biomed. 2008 Nov;21(10):1043-56 [18615861.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):530-6 [19147017.001]
  • [Cites] Eur J Radiol. 2009 Apr;70(1):180-9 [18541399.001]
  • [Cites] J Neurosurg. 2000 Feb;92(2):326-33 [10659021.001]
  • [Cites] IEEE Trans Biomed Eng. 2000 Feb;47(2):259-65 [10721633.001]
  • [Cites] Clin Exp Metastasis. 1992 Sep;10(5):345-50 [1505124.001]
  • [Cites] J Neurooncol. 1991 Dec;11(3):185-97 [1823340.001]
  • [Cites] Int J Cancer. 1992 Sep 30;52(3):409-13 [1399117.001]
  • [Cites] Cancer Res. 1993 Jan 1;53(1):176-82 [8416743.001]
  • [Cites] Science. 1993 Jan 1;259(5091):94-7 [8418502.001]
  • [Cites] J Neurosurg. 1993 Nov;79(5):729-35 [8410252.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Mar 30;28(5):1067-77 [8175391.001]
  • [Cites] J Neurooncol. 1994;19(3):259-68 [7807177.001]
  • [Cites] J Neurooncol. 1994;22(3):191-200 [7760095.001]
  • [Cites] J Surg Oncol. 1995 Jun;59(2):105-9 [7776650.001]
  • [Cites] Br J Cancer. 1995 Sep;72(3):607-14 [7669569.001]
  • [Cites] Leukemia. 1995 Oct;9 Suppl 1:S106-12 [7475300.001]
  • [Cites] Int J Cancer. 1995 Sep 15;62(6):767-71 [7558428.001]
  • [Cites] Hum Gene Ther. 1995 Nov;6(11):1467-76 [8573619.001]
  • [Cites] Cancer Lett. 1997 May 1;115(1):81-90 [9097982.001]
  • [Cites] Invasion Metastasis. 1996;16(3):107-15 [9186546.001]
  • [Cites] Klin Padiatr. 1997 Jul-Aug;209(4):275-7 [9293462.001]
  • [Cites] J Neurooncol. 1998 Jan;36(1):91-102 [9525831.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):2020-8 [9581848.001]
  • [Cites] Hum Gene Ther. 1999 Jan 1;10(1):95-101 [10022534.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):3861-5 [10463570.001]
  • [Cites] Cancer Gene Ther. 2004 Nov;11(11):721-32 [15475879.001]
  • [Cites] Pathobiology. 1999 Jul-Aug;67(4):202-6 [10738182.001]
  • [Cites] Gene Ther. 2000 Jun;7(12):993-9 [10871746.001]
  • [Cites] Cancer Gene Ther. 2000 Jun;7(6):879-84 [10880018.001]
  • [Cites] Cancer Gene Ther. 2000 Jun;7(6):947-53 [10880027.001]
  • [Cites] J Neurooncol. 2000;46(3):231-40 [10902854.001]
  • [Cites] J Biol Chem. 2000 Jul 28;275(30):22695-703 [10801887.001]
  • [Cites] Neurosurgery. 2000 Oct;47(4):993-9; discussion 999-1000 [11014444.001]
  • [Cites] Cancer Gene Ther. 2001 Jan;8(1):3-8 [11219491.001]
  • [Cites] Neurol Res. 2001 Jun;23(4):359-66 [11428516.001]
  • [Cites] J Neurooncol. 2001 Mar;52(1):37-47 [11451201.001]
  • [Cites] Histol Histopathol. 2001 Jul;16(3):735-44 [11510963.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7056-9 [11585735.001]
  • [Cites] J Neurooncol. 2001 Jul;53(3):275-87 [11718260.001]
  • [Cites] J Neurooncol. 2002 Jan;56(1):1-12 [11949821.001]
  • [Cites] Gene Ther. 2002 May;9(9):584-91 [11973634.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):143-8 [11995815.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Jun;301(3):838-51 [12023511.001]
  • [Cites] Med Oncol. 2002;19(1):1-9 [12025885.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Aug;61(8):725-35 [12152787.001]
  • [Cites] Gene Ther. 2002 Sep;9(17):1139-45 [12170377.001]
  • [Cites] Cancer Lett. 2003 Mar 20;192(1):97-107 [12637158.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1083-93 [12651601.001]
  • [Cites] Neoplasia. 2003 Jan-Feb;5(1):17-22 [12659666.001]
  • [Cites] J Neurooncol. 2003 Mar-Apr;62(1-2):61-74 [12749703.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3195-201 [12810648.001]
  • [Cites] J Neurooncol. 2003 May;63(1):1-7 [12814248.001]
  • [Cites] Ann Neurol. 2003 Sep;54(3):388-92 [12953273.001]
  • [Cites] Cell Immunol. 2003 Oct;225(2):113-21 [14698145.001]
  • [Cites] Gene Ther. 2004 Jan;11(2):161-9 [14712300.001]
  • [Cites] Gene Ther. 2004 Jan;11(2):214-23 [14712306.001]
  • [Cites] Mol Ther. 2004 Feb;9(2):282-91 [14759812.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2317-23 [15059878.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jul;146(7):731-4 [15197617.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5187-201 [15297423.001]
  • [Cites] Science. 1968 Jul 26;161(3839):370-1 [4873531.001]
  • [Cites] J Cell Physiol. 1970 Jun;75(3):329-39 [4988781.001]
  • [Cites] J Neurosurg. 1971 Mar;34(3):310-23 [4323142.001]
  • [Cites] J Neurosurg. 1971 Mar;34(3):335-40 [5547317.001]
  • [Cites] Cancer Res. 1973 May;33(5):976-86 [4703128.001]
  • [Cites] J Med. 1975;6(3-4):249-59 [1059719.001]
  • [Cites] J Natl Cancer Inst. 1975 Nov;55(5):1177-87 [1206744.001]
  • [Cites] Am J Pathol. 1976 Apr;83(1):149-76 [179328.001]
  • [Cites] Can J Neurol Sci. 2006 Feb;33(1):86-91 [16583728.001]
  • [Cites] Neurosurg Focus. 2006;20(4):E25 [16709031.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):989-98 [16741309.001]
  • [Cites] J Neurosci. 2006 Jun 21;26(25):6781-90 [16793885.001]
  • [Cites] J Neurooncol. 2006 Aug;79(1):9-17 [16575532.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5288-97 [17000661.001]
  • [Cites] NMR Biomed. 2006 Dec;19(8):1035-42 [16894643.001]
  • [Cites] Childs Nerv Syst. 2006 Dec;22(12):1519-25 [17021732.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):149-62 [16941073.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1260-8 [17317838.001]
  • [Cites] J Magn Reson. 2007 May;186(1):150-5 [17303454.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2728-37 [17473206.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4541-4 [17510377.001]
  • [Cites] Mol Ther. 2007 Jul;15(7):1373-81 [17457322.001]
  • [Cites] Stem Cells. 2007 Jul;25(7):1645-53 [17412894.001]
  • [Cites] Behav Brain Res. 2007 Aug 22;182(1):42-50 [17572515.001]
  • [Cites] Mol Cancer Ther. 2007 Aug;6(8):2290-302 [17699724.001]
  • [Cites] Neoplasia. 2007 Jul;9(7):546-55 [17710157.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5195-201 [17726137.001]
  • [Cites] Magn Reson Med. 2007 Sep;58(3):454-62 [17763344.001]
  • [Cites] Can J Neurol Sci. 2007 Aug;34(3):296-306 [17803026.001]
  • [Cites] J Neurooncol. 2007 Nov;85(2):191-202 [17557137.001]
  • (PMID = 19381449.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA150153; United States / NINDS NIH HHS / NS / R01 NS064607; United States / NINDS NIH HHS / NS / R21 NS056203; United States / NINDS NIH HHS / NS / K01 NS059575; United States / NINDS NIH HHS / NS / K01 NS059575-02; United States / NINDS NIH HHS / NS / R01 NS064607-01; United States / NINDS NIH HHS / NS / R21 NS056203-02
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 149
  • [Other-IDs] NLM/ NIHMS127810; NLM/ PMC2730996
  •  go-up   go-down


42. Fouladi M, Stewart CF, Blaney SM, Onar-Thomas A, Schaiquevich P, Packer RJ, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ: Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J Clin Oncol; 2010 Sep 20;28(27):4221-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
  • PURPOSE: To estimate the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetic properties of lapatinib, a selective epidermal growth factor receptor (EGFR) and ERBB2 inhibitor, in children with refractory or recurrent CNS malignancies.
  • Expression of the four ERBB receptors and downstream signaling elements in tumor tissue was evaluated by immunohistochemistry.
  • Frequent, high-level expression of activated (phosphorylated) EGFR and ERBB2 receptors and downstream signal intermediates were observed in tumors, particularly in ependymomas that displayed prolonged stable disease on lapatinib therapy.
  • CONCLUSION: Lapatinib is well tolerated in children with recurrent CNS malignancies, with rash, diarrhea, and fatigue identified as DLTs.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Central Nervous System Neoplasms / drug therapy. Protein Kinase Inhibitors / administration & dosage. Quinazolines / administration & dosage
  • [MeSH-minor] Administration, Oral. Adolescent. Child. Child, Preschool. Diarrhea / chemically induced. Exanthema / chemically induced. Fatigue / chemically induced. Female. Humans. Infant. Male. Maximum Tolerated Dose. Phosphorylation. Receptor, Epidermal Growth Factor / analysis. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, ErbB-2 / analysis. Receptor, ErbB-2 / antagonists & inhibitors. Steroids / therapeutic use. Treatment Outcome. United States. Young Adult

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2000 Jul 3;19(13):3159-67 [10880430.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 Jan;65(2):353-61 [19499221.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] Oncogene. 2002 Sep 12;21(41):6255-63 [12214266.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3054-64 [12374672.001]
  • [Cites] Mol Cancer Ther. 2001 Dec;1(2):85-94 [12467226.001]
  • [Cites] Lancet Oncol. 2003 Jul;4(7):397-406 [12850190.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3620-4 [14506149.001]
  • [Cites] Mol Cell. 2003 Sep;12(3):541-52 [14527402.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):984-93 [14970185.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):317-28 [15093539.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jun 18;319(1):1-11 [15158434.001]
  • [Cites] Oncologist. 2004;9 Suppl 3:10-5 [15163842.001]
  • [Cites] Mol Cell Biol. 1989 Mar;9(3):1165-72 [2566907.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4838-48 [9354447.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):786-92 [15728811.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5305-13 [15955900.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Feb 2;831(1-2):169-75 [16364699.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1630-9 [16452222.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16 [16829981.001]
  • [Cites] Trends Cell Biol. 2006 Dec;16(12):649-56 [17085050.001]
  • [Cites] N Engl J Med. 2006 Dec 28;355(26):2733-43 [17192538.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3137-43 [17634493.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3397-8 [17635950.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3753-8 [17704424.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):1993-9 [18421051.001]
  • [Cites] Semin Oncol. 2008 Jun;35(3):286-97 [18544443.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4484-90 [18628463.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4921-7 [18794549.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1452-9 [19228746.001]
  • [Cites] J Biopharm Stat. 2009;19(3):437-55 [19384687.001]
  • [Cites] Clin Pharmacol Ther. 2000 Oct;68(4):356-66 [11061575.001]
  • (PMID = 20713864.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA129541; United States / NCI NIH HHS / CA / U01 CA081457; United States / NCI NIH HHS / CA / U01CA81457
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0 / Steroids; 0VUA21238F / lapatinib; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2953974
  •  go-up   go-down


43. Sheedy SP, Welker KM, DeLone DR, Gilbertson JR: CNS metastases of carcinoma ex pleomorphic adenoma of the parotid gland. AJNR Am J Neuroradiol; 2006 Aug;27(7):1483-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS metastases of carcinoma ex pleomorphic adenoma of the parotid gland.
  • Pleomorphic adenomas (PAs), also known as benign mixed tumors, are common tumors of the parotid gland.
  • These tumors occasionally undergo malignant transformation, with potentially devastating consequences.
  • [MeSH-major] Adenocarcinoma / secondary. Adenoma, Pleomorphic / pathology. Brain Neoplasms / secondary. Neoplasms, Multiple Primary / pathology. Parotid Neoplasms / pathology. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16908563.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Adams DM, Zhou T, Berg SL, Bernstein M, Neville K, Blaney SM, Children's Oncology Group: Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study. Pediatr Blood Cancer; 2008 Mar;50(3):549-53
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study.
  • O(6)-benzylguanine (O(6)-BG), an inhibitor of host alkylation repair, and BCNU were studied in children with refractory/untreatable central nervous system tumors to determine dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of BCNU administered following O(6)-BG.
  • Once the MTD was exceeded, Stage II accrual was limited to less heavily pretreated patients (</= two prior chemotherapy regimens, no prior central axis radiation, no prior bone marrow transplant, and no bone marrow involvement).
  • CONCLUSIONS: Based on lack of activity of this combination in adult phase II studies, no further testing of O(6)-BG plus BCNU in children is planned.
  • [MeSH-major] Antineoplastic Agents, Alkylating / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carmustine / pharmacology. Central Nervous System Neoplasms / drug therapy. Guanine / analogs & derivatives. Neoplasm Proteins / antagonists & inhibitors. O(6)-Methylguanine-DNA Methyltransferase / antagonists & inhibitors
  • [MeSH-minor] Adolescent. Bone Marrow Diseases / chemically induced. Child. Child, Preschool. Cohort Studies. Combined Modality Therapy. DNA Repair / drug effects. DNA, Neoplasm / drug effects. Enzyme Inhibitors / administration & dosage. Enzyme Inhibitors / pharmacology. Enzyme Inhibitors / therapeutic use. Female. Humans. Male. Maximum Tolerated Dose. Salvage Therapy

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17941066.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 97543; United States / NCRR NIH HHS / RR / M01 RR00188; United States / NCI NIH HHS / CA / U01 CA97552
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / DNA, Neoplasm; 0 / Enzyme Inhibitors; 0 / Neoplasm Proteins; 19916-73-5 / O(6)-benzylguanine; 5Z93L87A1R / Guanine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; U68WG3173Y / Carmustine
  •  go-up   go-down


45. Sonoda Y, Matsumoto K, Kakuto Y, Nishino Y, Kumabe T, Tominaga T, Katakura R: Primary CNS lymphoma treated with combined intra-arterial ACNU and radiotherapy. Acta Neurochir (Wien); 2007 Nov;149(11):1183-9; discussion 1189
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary CNS lymphoma treated with combined intra-arterial ACNU and radiotherapy.
  • OBJECT: To assess whether nimustine (ACNU), a drug that can cross the blood brain barrier, combined with radiotherapy, improved the survival of patients with primary central nervous system lymphoma (PCNSL).
  • By multivariate analysis, age (<60 vs. > or =60 years) was the only statistically significant prognostic factor; the WBRT dose, sex, and number of tumors were not significant prognostic factors in this study.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Cranial Irradiation. Infusions, Intra-Arterial. Lymphoma, B-Cell / drug therapy. Lymphoma, T-Cell / drug therapy. Nimustine / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17712511.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0S726V972K / Nimustine
  •  go-up   go-down


46. Weil RJ, Lonser RR: Selective excision of metastatic brain tumors originating in the motor cortex with preservation of function. J Clin Oncol; 2005 Feb 20;23(6):1209-17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective excision of metastatic brain tumors originating in the motor cortex with preservation of function.
  • PATIENTS AND METHODS: Seventeen consecutive patients with metastasis within the primary motor cortex underwent selective microsurgical tumor resection.
  • Motor cortex was identified and tumor (mean volume, 10.2 cm(3)) was completely resected in all patients.
  • The cause of death in 14 of 15 patients who have died was progressive systemic disease; in one patient it was a combination of systemic and distant CNS disease progression.
  • There were no local CNS recurrences.
  • CONCLUSION: Complete microsurgical resection of metastatic tumors in the primary motor cortex is feasible and efficacious, results in a sustained improvement in performance outcomes, and permits satisfactory long-term survival.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Motor Cortex
  • [MeSH-minor] Adult. Aged. Feasibility Studies. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Microsurgery. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15718318.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jäger D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C, von Deimling A: Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol; 2010 Jan;20(1):245-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.
  • Here we investigate the capability of this antibody to differentiate wild type and mutated IDH1 protein in central nervous system (CNS) tumors by Western blot and immunohistochemistry.
  • In Western blot, anti-IDH1R132H mouse monoclonal antibody mIDH1R132H detected a specific band only in mutated tumors.
  • Immunohistochemistry of 345 primary brain tumors demonstrated a strong cytoplasmic and weaker nuclear staining in 122 cases.
  • Intriguing is the ability of mIDH1R132H to detect single infiltrating tumor cells.
  • The very high frequency and the distribution of this mutation among specific brain tumor entities allow the highly sensitive and specific discrimination of various tumors by immunohistochemistry, such as anaplastic astrocytoma from primary glioblastoma or diffuse astrocytoma World Health Organization (WHO) grade II from pilocytic astrocytoma or ependymoma.
  • Noteworthy is the discrimination of the infiltrating edge of tumors with IDH1 mutation from reactive gliosis.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / enzymology. Brain Neoplasms / genetics. Ependymoma / genetics. Glioma / enzymology. Glioma / genetics. Isocitrate Dehydrogenase / genetics. Isocitrate Dehydrogenase / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigen-Antibody Reactions. Blotting, Western. Child. Child, Preschool. Cloning, Molecular. DNA, Neoplasm / biosynthesis. DNA, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Mutation / genetics. Mutation / physiology. Protein Biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19903171.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human
  •  go-up   go-down


48. Kosaka N, Tsuchida T, Uematsu H, Kimura H, Okazawa H, Itoh H: 18F-FDG PET of common enhancing malignant brain tumors. AJR Am J Roentgenol; 2008 Jun;190(6):W365-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG PET of common enhancing malignant brain tumors.
  • OBJECTIVE: The purpose of our study was to determine whether (18)F-FDG PET can be used to differentiate among common enhancing brain tumors such as lymphoma, high-grade glioma, and metastatic brain tumor.
  • MATERIALS AND METHODS: We evaluated 34 patients with an enhancing brain tumor on MRI, including seven lymphomas, nine high-grade gliomas, and 18 metastatic tumors.
  • For PET image analysis, regions of interest were placed over the tumor (T), contralateral cortex (C), and white matter (WM).
  • RESULTS: All parameters were significantly higher for lymphoma than for other tumors (p < 0.01).
  • High-grade gliomas showed significantly higher SUV(avg) and SUV(max) than metastatic tumors (p < 0.05).
  • Using an SUV(max) of 15.0 as a cutoff for diagnosing CNS lymphoma, only one high-grade glioma was found as a false-positive (SUV(max), 18.8).
  • CONCLUSION: FDG PET may be useful for differentiating common enhancing malignant brain tumors, particularly lymphoma versus high-grade glioma and metastatic tumor.
  • FDG PET can provide useful information for distinguishing between lymphoma and other malignant enhancing brain tumors and is recommended when differential diagnoses are difficult to narrow using MRI alone.
  • [MeSH-major] Algorithms. Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods. Positron-Emission Tomography / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18492879.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


49. Kamoshima Y, Sawamura Y: Update on current standard treatments in central nervous system germ cell tumors. Curr Opin Neurol; 2010 Dec;23(6):571-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on current standard treatments in central nervous system germ cell tumors.
  • PURPOSE OF REVIEW: Various approaches have been used for the management of patients with germ cell tumors (GCTs) in the central nervous system (CNS); however, the optimal treatment of both germinoma and nongerminomatous GCTs remains unknown.
  • This review discusses current management strategies and late effects of therapy for CNS GCTs.
  • SUMMARY: The 10-year survival rate of CNS germinoma is approximately 90%.
  • Most patients with CNS GCTs are children and young adults.
  • Therefore, with the improving life prognosis of young patients, secondary neoplasms, secondary cerebral vasculopathy, neurocognitive deficits, and many other adverse effects induced by the initial treatments are problems to be solved in the next decade.
  • [MeSH-major] Antineoplastic Protocols / standards. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / radiotherapy
  • [MeSH-minor] Adolescent. Antineoplastic Agents / chemistry. Antineoplastic Agents / pharmacology. Antineoplastic Combined Chemotherapy Protocols / standards. Child. Germinoma / drug therapy. Germinoma / mortality. Germinoma / radiotherapy. Humans. Survival Rate / trends. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20885323.001).
  • [ISSN] 1473-6551
  • [Journal-full-title] Current opinion in neurology
  • [ISO-abbreviation] Curr. Opin. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


50. Yang SH, Lee KS, Kim IS, Hong JT, Sung JH, Son BC, Lee SW, Hong YK: Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy: role of STAT6 activation as prognostic determinant. J Neurooncol; 2009 Mar;92(1):65-71
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy: role of STAT6 activation as prognostic determinant.
  • We report a single-center experience of 16 immunocompetent patients diagnosed with primary central nervous system lymphoma and treated with monochemotherapy with high-dose methotrexate (MTX) and deferred radiotherapy.
  • There were eight complete responses (CR), one partial response, one stable disease, and six patients whose tumors progressed in spite of the chemotherapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Central Nervous System Neoplasms / metabolism. Lymphoma, Non-Hodgkin / metabolism. Methotrexate / administration & dosage. STAT6 Transcription Factor / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19030780.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / STAT6 Transcription Factor; 0 / STAT6 protein, human; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


51. Malkarov MS, Dreval' ON, Gorozhanin AV, Puchkov VL, Rynkov IP, Kuznetsov AV, Chagava AD: [Methods of intraoperative control in resection of intraparenchymal brain tumors]. Zh Vopr Neirokhir Im N N Burdenko; 2010 Jul-Sep;(3):20-5; discussion 25
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Methods of intraoperative control in resection of intraparenchymal brain tumors].
  • Primary CNS tumors represent 1.4% of all malignant neoplasias and 2.4% of total oncological mortality.
  • The principal goal of tumor resection is maximally possible radical removal with minimal injury of normal brain tissue.
  • In conditions of altered anatomy ultrasonographic guidance is intended to optimize approach to intracerebral tumors considering eloquent areas and main vessels.
  • Fluorescent guidance provides possibility of visual differentiation of tumor and normal tissue thus defining the borderline.
  • Combination of these two techniques may lead to more radical resection of tumors and minimize injury of normal brain.
  • We operated 70 patients with primary and metastatic intraparenchymal brain tumors.
  • [MeSH-major] Brain Neoplasms / surgery. Brain Neoplasms / ultrasonography. Monitoring, Physiologic / methods. Neurosurgical Procedures / methods. Ultrasonography, Doppler, Transcranial / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Intraoperative Period. Male. Middle Aged. Postoperative Complications / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21254572.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


52. Gammon DC, Bhatt MS, Tran L, Van Horn A, Benvenuti M, Glantz MJ: Intrathecal topotecan in adult patients with neoplastic meningitis. Am J Health Syst Pharm; 2006 Nov 1;63(21):2083-6
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrathecal topotecan in adult patients with neoplastic meningitis.
  • Three patients developed NM in the setting of systemic cancer; 11 patients had primary central nervous system (CNS) malignancies.
  • Of the 11 patients with primary CNS tumors, 6 patients achieved CSF clearing after the first dose of intrathecal topotecan, 2 patients after the second dose, and 1 patient after the fifth dose.
  • For the 3 patients with secondary CSF tumors, 1 patient achieved CSF clearing after the third dose and 2 patients did not reach the primary endpoint.
  • CONCLUSION: Intrathecal topotecan appeared to be effective and safe in adult patients with NM.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Injections, Spinal. Meningeal Neoplasms / drug therapy. Topotecan / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17057045.001).
  • [ISSN] 1079-2082
  • [Journal-full-title] American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • [ISO-abbreviation] Am J Health Syst Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7M7YKX2N15 / Topotecan
  •  go-up   go-down


53. Sakurada K, Saino M, Mouri W, Sato A, Kitanaka C, Kayama T: Nestin expression in central nervous system germ cell tumors. Neurosurg Rev; 2008 Apr;31(2):173-6; discussion 176-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nestin expression in central nervous system germ cell tumors.
  • Central nervous system (CNS) germ cell tumors constitute a unique class of rare tumors that mainly affect children and adolescents.
  • These tumors are believed to originate from displaced primordial germ cells.
  • Recently, results of treatment of germ cell tumors have improved with use of radiotherapy and combination chemotherapy.
  • However, some tumors have proven refractory to intensive treatment with surgery, radiation, and combination chemotherapy.
  • Nestin is an intermediate filament protein expressed in undifferentiated cells during CNS development and in CNS tumors and is used as a marker of immature elements of tumors, including brain tumor stem cells.
  • In this study, we examined for the first time nestin expression in 19 CNS germ cell tumors (nine pure germinomas, five germinomas with syncytiotrophoblastic giant cells, one yolk sac tumor, one choriocarcinoma, one embryonal carcinoma, and two mature teratomas).
  • Clinically, nestin-negative tumors did not exhibit dissemination, while all tumors that exhibited dissemination also strongly expressed nestin protein.
  • These findings suggest that the detection of nestin expression could be useful in the management of CNS germ cell tumors, as an auxiliary predictor of dissemination and/or progression.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Central Nervous System Neoplasms / genetics. Intermediate Filament Proteins / biosynthesis. Intermediate Filament Proteins / genetics. Neoplasms, Germ Cell and Embryonal / genetics. Nerve Tissue Proteins / biosynthesis. Nerve Tissue Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Choriocarcinoma / genetics. Choriocarcinoma / metabolism. Choriocarcinoma / pathology. Endodermal Sinus Tumor / genetics. Endodermal Sinus Tumor / metabolism. Endodermal Sinus Tumor / pathology. Female. Germinoma / genetics. Germinoma / metabolism. Germinoma / pathology. Giant Cell Tumors / genetics. Giant Cell Tumors / metabolism. Giant Cell Tumors / pathology. Humans. Hypopituitarism / etiology. Immunoenzyme Techniques. Magnetic Resonance Imaging. Male. Nestin. Teratoma / genetics. Teratoma / metabolism. Teratoma / pathology. Vision Disorders / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1999 Feb;90(2):258-64 [9950496.001]
  • [Cites] Cell Mol Life Sci. 2004 Oct;61(19-20):2510-22 [15526158.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):222-3 [15677549.001]
  • [Cites] APMIS. 2002 Jun;110(6):499-507 [12193211.001]
  • [Cites] Neurosci Lett. 2006 May 29;400(1-2):80-5 [16529857.001]
  • [Cites] Neurosurg Focus. 1998 Jul 15;5(1):e7 [17140188.001]
  • [Cites] J Histochem Cytochem. 2002 Feb;50(2):147-58 [11799134.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):345-51 [11896213.001]
  • [Cites] Mol Cancer. 2006 Dec 02;5:67 [17140455.001]
  • [Cites] Neurol Res. 1989 Jun;11(2):118-26 [2569683.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):781-6 [14711994.001]
  • [Cites] J Neurooncol. 2001 Sep;54(3):311-6 [11767296.001]
  • [Cites] J Invest Dermatol. 2006 Jan;126(1):142-53 [16417230.001]
  • (PMID = 18092184.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


54. Ogino H, Shibamoto Y, Takanaka T, Suzuki K, Ishihara S, Yamada T, Sugie C, Nomoto Y, Mimura M: CNS germinoma with elevated serum human chorionic gonadotropin level: clinical characteristics and treatment outcome. Int J Radiat Oncol Biol Phys; 2005 Jul 1;62(3):803-8
Genetic Alliance. consumer health - Germinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS germinoma with elevated serum human chorionic gonadotropin level: clinical characteristics and treatment outcome.
  • PURPOSE: The prognostic significance of human chorionic gonadotropin (HCG) level in central nervous system germinoma remains controversial.
  • METHODS AND MATERIALS: We undertook a multi-institutional retrospective analysis of 103 patients with central nervous system germinoma whose serum HCG and/or beta-HCG level had been measured before treatment between 1984 and 2002.
  • The proportion of HCG-producing tumors was higher in the lesions at the basal ganglia than in the lesions at the other sites.
  • No correlation was found between tumor size and HCG level, but there seemed to be a weak correlation between size and beta-HCG.
  • Also, no other patient-, tumor-, or treatment-related factors seemed to influence the prognosis of the patients.
  • Relationship between tumor size and site and HCG level should be investigated further.
  • [MeSH-major] Central Nervous System Neoplasms / blood. Chorionic Gonadotropin / blood. Germinoma / blood. Neoplasm Proteins / blood
  • [MeSH-minor] Adolescent. Adult. Chorionic Gonadotropin, beta Subunit, Human / blood. Female. Humans. Male. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936563.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / Neoplasm Proteins
  •  go-up   go-down


55. Barresi V, Tuccari G, Barresi G: NGAL immunohistochemical expression in brain primary and metastatic tumors. Clin Neuropathol; 2010 Sep-Oct;29(5):317-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NGAL immunohistochemical expression in brain primary and metastatic tumors.
  • A significant association has been recently shown between the expression of neutrophil gelatinase-associated lipocalin (NGAL) in tumors and its urinary levels.
  • Thus NGAL urinary detection has been proposed as a method for the early diagnosis of brain tumors.
  • In view of this, the objective of this study was to investigate whether NGAL expression differs according to brain tumor type or in primary vs. metastatic brain neolasias.
  • 42 surgically resected formalin fixed and paraffin embedded neoplasias, including 15 cases of brain metastasis and 27 cases of primary central nervous system (CNS) tumors (11 meningiomas; 1 pilocytic astrocytoma, 2 diffuse astrocytomas, 2 oligoastrocytomas, 2 oligodendrogliomas, 1 anaplastic oligoastrocytoma, 7 glioblastomas, 1 ependymoma) were submitted to the immunohistochemical procedure.
  • A statistically significant correlation was demonstrated between NGAL presence and high proliferation index in the primary tumors.
  • In conclusion, our findings suggest that NGAL expression is restricted to high grade gliomas among primary brain tumors, and that brain metastases do not express this protein.
  • Considering the correlation between NGAL expression in tumors and its urinary levels, if our observations will be further validated, NGAL urinary detection might be used as an additional tool in the pre-surgical definition of brain lesions involving difficult differential diagnosis.
  • [MeSH-major] Acute-Phase Proteins / metabolism. Brain Neoplasms / metabolism. Brain Neoplasms / secondary. Lipocalins / metabolism. Proto-Oncogene Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20860895.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Acute-Phase Proteins; 0 / LCN2 protein, human; 0 / Lipocalins; 0 / Proto-Oncogene Proteins
  •  go-up   go-down


56. Vasudevan V, Cheung MC, Yang R, Zhuge Y, Fischer AC, Koniaris LG, Sola JE: Pediatric solid tumors and second malignancies: characteristics and survival outcomes. J Surg Res; 2010 May 15;160(2):184-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric solid tumors and second malignancies: characteristics and survival outcomes.
  • BACKGROUND: To examine the incidence, characteristics, and outcomes for second malignancies following the diagnosis of a primary solid tumor in pediatric patients.
  • Mean age at diagnosis of the primary tumor was 7.7 y.
  • The most common primary malignancies were CNS tumors (22.5%), followed by soft tissue sarcoma (15.8%), retinoblastoma (14.1%), and bone tumors (13%).
  • Hematologic malignancies (35.5%) were the most common second malignancies noted in the cohort, followed by bone tumors (18%) and soft tissue sarcomas (15%).
  • Hematologic malignancies had a shorter latency (3.1 y) compared with solid second tumors (11.6 y).
  • For most tumor categories, development of a secondary malignancy was associated with lower 5- and 10-y survival than expected.
  • CONCLUSIONS: CNS tumors, retinoblastoma, and soft tissue sarcomas in children are the most common solid primary tumors, with an increased risk of a second malignancy.
  • Leukemia is the most common second malignancy seen in pediatric solid tumors.
  • [MeSH-major] Neoplasms / mortality. Neoplasms, Second Primary / mortality. SEER Program
  • [MeSH-minor] Adolescent. Bone Neoplasms / mortality. Central Nervous System Neoplasms / mortality. Child. Child, Preschool. Female. Follow-Up Studies. Hematologic Neoplasms / mortality. Humans. Incidence. Male. Retinoblastoma / mortality. Sarcoma / mortality. Soft Tissue Neoplasms / mortality. Survival Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19765728.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Fuller CE, Perry A: Molecular diagnostics in central nervous system tumors. Adv Anat Pathol; 2005 Jul;12(4):180-94
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular diagnostics in central nervous system tumors.
  • Central nervous system (CNS) neoplasms can be diagnostically challenging, due to remarkably wide ranges in histologic appearance, biologic behavior, and therapeutic approach.
  • In this regard, the field is primed by recent advances in basic research, elucidating the molecular mechanisms of tumorigenesis and progression in the most common adult and pediatric brain tumors.
  • Thus far, few have made the transition into routine clinical practice, the most notable example being 1p and 19q testing in oligodendroglial tumors.
  • The goal of this article is to highlight the most common genetic alterations currently implicated in CNS tumors, focusing most on those that are either already in common use in ancillary molecular diagnostics testing or are likely to become so in the near future.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Central Nervous System Neoplasms / genetics. Ependymoma / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Animals. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Chromosome Aberrations. Humans. In Situ Hybridization, Fluorescence. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / genetics. Meningioma / diagnosis. Meningioma / genetics. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / genetics. Polymerase Chain Reaction. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096380.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 260
  •  go-up   go-down


58. Kurwale NS, Ahmad FU, Satyarthi G, Suri A, Mahapatra AK: Can radiation induce pituitary tumors? Giant prolactinoma after radiation exposure. J Clin Neurosci; 2008 Nov;15(11):1287-8
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can radiation induce pituitary tumors? Giant prolactinoma after radiation exposure.
  • Radiation is a well-known etiology for many CNS tumors, including meningiomas, sarcomas and gliomas.
  • The role of radiation exposure in the etiology of pituitary adenoma is discussed, along with a literature review of radiation-induced tumors.
  • [MeSH-major] Neoplasms, Radiation-Induced. Pituitary Neoplasms / etiology. Prolactinoma / etiology. Radiotherapy, High-Energy / adverse effects
  • [MeSH-minor] Brain Stem Neoplasms / radiotherapy. Glioma / radiotherapy. Humans. Magnetic Resonance Imaging / methods. Male. Tomography, X-Ray Computed. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18829328.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


59. Killory BD, Chang SW, Wait SD, Spetzler RF: Use of flexible hollow-core CO2 laser in microsurgical resection of CNS lesions: early surgical experience. Neurosurgery; 2010 Jun;66(6):1187-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of flexible hollow-core CO2 laser in microsurgical resection of CNS lesions: early surgical experience.
  • The laser was not helpful with highly vascular tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Brain Neoplasms / pathology. Brain Neoplasms / physiopathology. Brain Neoplasms / surgery. Child. Female. Hemangioma, Cavernous, Central Nervous System / pathology. Hemangioma, Cavernous, Central Nervous System / physiopathology. Hemangioma, Cavernous, Central Nervous System / surgery. Humans. Male. Meningeal Neoplasms / pathology. Meningeal Neoplasms / physiopathology. Meningeal Neoplasms / surgery. Middle Aged. Prospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495434.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Gonçalves MI, Radzinsky TC, da Silva NS, Chiari BM, Consonni D: Speech-language and hearing complaints of children and adolescents with brain tumors. Pediatr Blood Cancer; 2008 Mar;50(3):706-8
MedlinePlus Health Information. consumer health - Speech and Language Problems in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Speech-language and hearing complaints of children and adolescents with brain tumors.
  • Central nervous system (CNS) tumors generally leave sequelae that may compromise speech, language, swallowing, hearing, and voice functions.
  • This report describes the incidence of speech-language and hearing complaints and disorders in children and adolescents with CNS tumor under treatment at one of the most important Brazilian reference center for pediatric cancer.
  • [MeSH-major] Brain Neoplasms / complications. Hearing Loss / etiology. Language Disorders / etiology. Speech Disorders / etiology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Astrocytoma / complications. Astrocytoma / drug therapy. Child. Child, Preschool. Craniopharyngioma / complications. Craniopharyngioma / drug therapy. Deglutition Disorders / etiology. Ependymoma / complications. Ependymoma / drug therapy. Facial Paralysis / etiology. Female. Humans. Infant. Male. Medulloblastoma / complications. Medulloblastoma / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Speech and Communication Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17534932.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


61. Sasayama T, Nishihara M, Tanaka K, Mizukawa K, Ehara K, Kanomata N, Kohmura E: Two metachronous tumors induced by radiation therapy: case report and review of the literature. J Neurooncol; 2008 Jul;88(3):315-20
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two metachronous tumors induced by radiation therapy: case report and review of the literature.
  • Various radiation-induced tumors, including meningioma, glioma, and sarcoma, have been reported; however, metachronous intracranial double tumors induced by radiation therapy are extremely rare.
  • A 1-year-old boy had undergone tumor removal and craniospinal radiation therapy (30 Gy) for cerebellar medulloblastoma.
  • Six years later, an infiltrative tumor was newly found in the right fronto-temporal white matter.
  • The patient underwent stereotactic biopsy, and the tumor was found to be an anaplastic astrocytoma.
  • Since both secondary tumors were located within the area of previous radiation and the patient did not have any genetic disease predisposing him to tumors, radiation therapy was considered to be responsible for their tumorigenesis.
  • To our knowledge, this case is the fourth case of radiation-induced double CNS tumors arising after radiotherapy to be described in the literature.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasms, Radiation-Induced / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adult. Age of Onset. Cerebellar Neoplasms / radiotherapy. Cranial Irradiation / adverse effects. Humans. In Situ Hybridization, Fluorescence. Infant. Loss of Heterozygosity. Magnetic Resonance Imaging. Male. Medulloblastoma / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18373066.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


62. Riva D, Massimino M, Giorgi C, Nichelli F, Erbetta A, Usilla A, Vago C, Bulgheroni S: Cognition before and after chemotherapy alone in children with chiasmatic-hypothalamic tumors. J Neurooncol; 2009 Mar;92(1):49-56

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cognition before and after chemotherapy alone in children with chiasmatic-hypothalamic tumors.
  • Studies on adults with cancer, with or without CNS involvement, have shown that chemotherapy (CT) can affect cognitive functions.
  • Among 18 children with chiasmatic-hypothalamic tumors (CHT) given front-line CT treatment at our institute using the same protocol (cisplatin and etoposide), we screened eight children for cognitive sequelae, correlating their test performance with several clinical variables (age at diagnosis and at time of treatment, time elapsing since treatment, and tumor volume reduction).
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cognition / drug effects. Hypothalamic Neoplasms / drug therapy. Optic Chiasm / drug effects. Optic Nerve Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Age of Onset. Child. Child, Preschool. Humans. Infant. Neuropsychological Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19005618.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


63. Moise D, Madhusoodanan S: Psychiatric symptoms associated with brain tumors: a clinical enigma. CNS Spectr; 2006 Jan;11(1):28-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychiatric symptoms associated with brain tumors: a clinical enigma.
  • Patients in psychiatric settings may present with medical conditions, such as brain tumors, which may or may not be associated with neurological symptoms.
  • Brain tumors may be detected in patients at their first presentation to mental health services or sometimes in patients with well-established psychiatric diagnoses.
  • Brain imaging showed the presence of a left thalamic tumor, later confirmed as glioblastoma multiforme.
  • With this we show that in some cases, brain tumors can be neurologically silent and only present atypical psychiatric symptoms.
  • [MeSH-major] Brain Neoplasms / complications. Depressive Disorder, Major / etiology. Stress Disorders, Post-Traumatic / etiology
  • [MeSH-minor] Adult. Female. Functional Laterality. Humans. Severity of Illness Index. Thalamus / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Post-Traumatic Stress Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400253.001).
  • [ISSN] 1092-8529
  • [Journal-full-title] CNS spectrums
  • [ISO-abbreviation] CNS Spectr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Zhang D, Hu LB, Henning TD, Ravarani EM, Zou LG, Feng XY, Wang WX, Wen L: MRI findings of primary CNS lymphoma in 26 immunocompetent patients. Korean J Radiol; 2010 May-Jun;11(3):269-77
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI findings of primary CNS lymphoma in 26 immunocompetent patients.
  • OBJECTIVE: To record the MR imaging features of primary central nervous system lymphoma (PCNSL) and compare these features in monofocal and multifocal disease.
  • Tumor location, tumor size, signal intensity, enhancement characteristics, age distribution, peritumoral edema, cystic changes, and the presence of calcifications were assessed.
  • Tumor size differed significantly between the two groups (t = 3.129, p < 0.01) and mildly or moderately enhanced lesions were more frequently found in the monofocal group (p < 0.05).
  • Monofocal PCNSL cases typically have larger sized tumors with mild or moderate enhancement.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / pathology. Immunocompetence. Lymphoma / pathology. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Contrast Media. Female. Gadolinium DTPA. Humans. Image Enhancement / methods. Male. Middle Aged. Observer Variation. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Tumor Pathol. 1999;16(1):29-35 [10532421.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):199-201 [10563423.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):219-26 [10563426.001]
  • [Cites] Neuroradiology. 1999 Nov;41(11):820-5 [10602854.001]
  • [Cites] Neurology. 2000 Apr 11;54(7):1427-33 [10751251.001]
  • [Cites] Neuroradiology. 2000 Oct;42(10):738-41 [11110076.001]
  • [Cites] AJR Am J Roentgenol. 2001 May;176(5):1319-26 [11312202.001]
  • [Cites] Eur Radiol. 2002 Feb;12(2):329-40 [11870430.001]
  • [Cites] Clin Neurol Neurosurg. 2003 Apr;105(2):78-86 [12691795.001]
  • [Cites] Clin Radiol. 1982 May 3;33(3):331-6 [7075140.001]
  • [Cites] Neuroradiology. 1984;26(6):485-92 [6504318.001]
  • [Cites] AJR Am J Roentgenol. 1986 Feb;146(2):271-6 [3484575.001]
  • [Cites] J Neurosurg. 1986 Nov;65(5):592-9 [3772444.001]
  • [Cites] Radiology. 1988 Apr;167(1):211-5 [3279454.001]
  • [Cites] J Neurosurg. 1988 Jun;68(6):835-53 [3286832.001]
  • [Cites] Neuroradiology. 1992;34(1):36-42 [1553036.001]
  • [Cites] Ann Neurol. 1993 Mar;33(3):308-11 [8498814.001]
  • [Cites] Cancer. 1994 Aug 15;74(4):1383-97 [8055462.001]
  • [Cites] Clin Radiol. 1994 Oct;49(10):696-702 [7955832.001]
  • [Cites] Radiology. 1995 Jan;194(1):271-6 [7997566.001]
  • [Cites] J Neurosurg. 1995 Jan;82(1):77-82 [7815138.001]
  • [Cites] AJR Am J Roentgenol. 1995 Sep;165(3):626 [7645482.001]
  • [Cites] Neuroradiology. 1996 Jan;38(1):34-7 [8773272.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Mar;18(3):563-72 [9090424.001]
  • [Cites] Ann Oncol. 1997 Mar;8(3):227-34 [9137790.001]
  • [Cites] Radiographics. 1997 Nov-Dec;17(6):1497-526 [9397461.001]
  • [Cites] Clin Radiol. 1998 Jun;53(6):428-34 [9651058.001]
  • [Cites] Neurochirurgie. 1997;43(6):385-7 [9706618.001]
  • [Cites] Clin Neurol Neurosurg. 2004 Dec;107(1):55-63 [15567554.001]
  • [Cites] AJR Am J Roentgenol. 2005 May;184(5):1679-85 [15855138.001]
  • [Cites] J Neurooncol. 2005 Apr;72(2):169-77 [15925998.001]
  • [CommentIn] Korean J Radiol. 2010 Nov-Dec;11(6):702-3 [21076600.001]
  • (PMID = 20461180.001).
  • [ISSN] 2005-8330
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  • [Other-IDs] NLM/ PMC2864853
  • [Keywords] NOTNLM ; Brain neoplasm / Computed tomography (CT) / Lymphoma / Magnetic resonance (MR)
  •  go-up   go-down


65. Park DS, Chung MK, Chung JI, Ahn HJ, Lee ES, Choi HY, Yoon DK, Cheon J, Hong SJ, Lee YG, Yoon SM, Kim WJ, Kim HJ, Ryu SB, Ro JY: Histologic type, staging, and distribution of germ cell tumors in Korean adults. Urol Oncol; 2008 Nov-Dec;26(6):590-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic type, staging, and distribution of germ cell tumors in Korean adults.
  • OBJECTIVES: To investigate the presentation of germ cell tumors (GCT) in terms of histology and stage, to better clarify the epidemiology of this disease in eastern Asia.
  • Clinical parameters at the time of initial diagnosis were classified in terms of the American Joint Committee on Cancer (AJCC) tumor, nodes, metastasis staging (TNMS) system, the International Germ Cell Cancer Collaborative Classification (IGCCC), for high-risk stage I nonseminomatous GCT (NSGCT) of testis.
  • RESULTS: The anatomic distributions for the primary sites of the observed tumors were as follows: testis 471 cases (67%); central nervous system (CNS) 137 cases (20%); mediastinum 78 cases (11%), and retroperitoneum 12 cases (2%); 239 (51%) of 471 tumors with testicular primary were seminoma.
  • Of NSGCT of testis, 129 (58%), 73 (33%), and 21 (9%) of tumors presented with good, intermediate, and poor prognosis, respectively, based on IGCCC, whereas 231 (99%) patients were classified with a good prognosis and 3 (1%) with an intermediate prognosis amongst seminomas of testis; 193 (82%) cases presented as stage I testicular seminoma whereas 120 (54%) cases presented as stage I NSGCT.
  • NSGCT presents itself as a more aggressive form whereas seminoma is a very indolent tumor when compared with cases in Western countries.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Korea / epidemiology. Male. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18367106.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Snoei J, Urbach H, Engels G, Fassunke J, von Lehe M, Becker AJ, Majores M: Genetic alterations of protein-o-mannosyltransferase-1 in glioneuronal and glial brain tumors with subarachnoid spread. Neuropathology; 2009 Apr;29(2):116-24
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alterations of protein-o-mannosyltransferase-1 in glioneuronal and glial brain tumors with subarachnoid spread.
  • Hypothesizing it as analogous in gliomas, we have performed a comprehensive polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis of the POMT1 gene in 41 brain tumor specimens.
  • Each specimen was subjected to laser capture microdissection analyses to dissect: (i) subarachnoid tumor components;.
  • (ii) deeply localized tumor areas; and (iii) histologically unaffected CNS fragments.
  • Exon 7 bore two sequence alterations, one 751C > T transition with amino acid exchange of arginine by tryptophane (Arg251Trp) (n = 12/41 in Tu vs n = 7/82 in Co) and a 752G > A transition with replacement of arginine by glutamine (Arg251Gln) (n = 3/41 in Tu vs n = 0/82 in Co) that were significantly increased in the tumor specimens compared to controls (P < 0.05).
  • We conclude that a significant increase of POMT1 missense mutations may indicate a functional role in neoplastic conditions in individual tumors.
  • Future studies will be important to evaluate a functional impact of POMT1 alterations in human brain tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Glioma / genetics. Mannosyltransferases / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Male. Microdissection. Middle Aged. Mutation, Missense. Polymerase Chain Reaction. Polymorphism, Genetic. Sequence Analysis, DNA. Subarachnoid Space. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18647264.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] EC 2.4.1.- / Mannosyltransferases; EC 2.4.1.109 / protein O-mannosyltransferase
  •  go-up   go-down


67. Erdamar S, Bagci P, Oz B, Dirican A: Correlation of endothelial nitric oxide synthase and vascular endothelial growth factor expression with malignancy in patients with astrocytic tumors. J BUON; 2006 Apr-Jun;11(2):213-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of endothelial nitric oxide synthase and vascular endothelial growth factor expression with malignancy in patients with astrocytic tumors.
  • PURPOSE: Many characteristics of malignant brain tumors (increased vascular permeability, vasodilatation, neovascularisation and free radical injury to the tumor and adjacent normal tissues) are believed to be mediated by nitric oxide (NO) synthetized by endothelial NO synthase (eNOS).
  • Overexpression of vascular endothelial growth factor (VEGF) is associated with several central nervous system (CNS) diseases and tumors.
  • Our aim was to study immunohistochemically the coexpression of eNOS and VEGF in astrocytic tumors and to analyse their possible correlation with tumor grade, angiogenesis and proliferation index.
  • MATERIALS AND METHODS: Sections from 120 randomly selected patients with supratentorial astrocytic tumors [38 glioblastomas (GB), 22 anaplastic astrocytomas (AA) and 20 low-grade astrocytomas (LA)], also including oligodendrogliomas (n=20) and mixed oligoastrocytomas (n=20), were immunostained with monoclonal antibodies for eNOS and VEGF using the avidin-biotin method.
  • The proliferative potential was assessed as the MIB-1 staining index for tumor cells.
  • CONCLUSION: Overexpressions of eNOS and VEGF in astrocytic tumors were significantly correlated with histological grade, proliferative potential and malignant transformation.
  • The expression of VEGF in a necrotic and ischemic tumor such as GB is more intense and diffuse than low-grade astrocytomas.
  • These findings suggest that eNOS overexpression in tumor vasculature would be precipitated by transformation into an angiogenic phenotype in the process of neovascularisation in astrocytic tumors.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Nitric Oxide Synthase Type III / biosynthesis. Vascular Endothelial Growth Factor A / biosynthesis
  • [MeSH-minor] Adult. Aged. Humans. Immunohistochemistry. Middle Aged. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17318973.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 1.14.13.39 / Nitric Oxide Synthase Type III
  •  go-up   go-down


68. Charboneau A, Chai J, Jordan J, Funkhouser W, Judkins A, Biegel J, Weissman B: P-Akt expression distinguishes two types of malignant rhabdoid tumors. J Cell Physiol; 2006 Nov;209(2):422-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P-Akt expression distinguishes two types of malignant rhabdoid tumors.
  • Highly aggressive pediatric malignant rhabdoid tumors (MRT) arise in the kidney and central nervous system (CNS) with no curative treatment available.
  • Multiple studies have shown that inactivation of the SNF5 tumor suppressor gene occurs in virtually all MRTs.
  • In this report, we demonstrate that phosphorylated Akt (P-Akt) is expressed in a subpopulation of cells in at least 10% of primary rhabdoid tumors as well as at high levels in three MRT cell lines.
  • Similar to other high P-Akt expressing tumor cell lines, MRTs have decreased sensitivity to p21 induced growth arrest.
  • Because drugs directed against the PI3-K/Akt have shown promise in clinical trials for other tumor types, they may prove useful for treatment of patients with P-Akt positive MRTs.
  • P-Akt expression also provides a potential mechanistic link between these pediatric tumors and adult malignancies.
  • [MeSH-major] Proto-Oncogene Proteins c-akt / metabolism. Rhabdoid Tumor / classification. Rhabdoid Tumor / pathology
  • [MeSH-minor] Cell Line, Tumor. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Humans. Mutant Proteins / metabolism. PTEN Phosphohydrolase / metabolism. Phosphorylation. Protein Transport. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - A204.1 (CVCL_L305) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16897758.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA46274; United States / NCI NIH HHS / CA / CA91048; United States / PHS HHS / / CAT3209156
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Mutant Proteins; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


69. Gutenberg A, Schulten HJ, Gunawan B, Ludwig HC, Brück W, Larsen J, Rohde V: CNS tumor 22 years after spinal neuroblastoma IV: diagnostic dilemma between recurrence and secondary malignancy. Pediatr Neurosurg; 2009;45(1):61-8
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS tumor 22 years after spinal neuroblastoma IV: diagnostic dilemma between recurrence and secondary malignancy.
  • We present the very unusual case of a young woman suffering from a brain tumor 22 years after a stage IV spinal neuroblastoma as an infant, demonstrating the difficulties of differentiating late neuroblastoma relapse from secondary supratentorial primitive neuroectodermal tumor (sPNET).
  • Lacking specific immunohistochemical features, the first cerebral tumor at the age of 21 was regarded as sPNET, and we pursued a therapeutic approach consisting of neurosurgical resection as well as irradiation and high-dose alkylator-based chemotherapy according to the HIT2000 protocol.
  • Moreover, the lack of PNET-specific translocations (EWS/FLI1 gene fusion) in both brain tumors as well as the development of hepatic metastases was more compatible with the diagnosis of a very late relapse 22 years after initial stage IV spinal neuroblastoma.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / pathology. Neuroblastoma / pathology. Spinal Neoplasms / pathology
  • [MeSH-minor] Adult. DNA, Neoplasm / genetics. Diagnosis, Differential. Female. Genetic Markers. Humans. Immunohistochemistry. Infant. Magnetic Resonance Imaging. Neoplasm Staging. Time Factors

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19258732.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers
  •  go-up   go-down


70. Sugita Y, Nakamura Y, Yamamoto M, Ogasawara S, Ohshima K, Shigemori M: Expression of KIAA 0864 protein in neuroepithelial tumors: an analysis based on the presence of monoclonal antibody HFB-16. J Neurooncol; 2008 Sep;89(2):151-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of KIAA 0864 protein in neuroepithelial tumors: an analysis based on the presence of monoclonal antibody HFB-16.
  • To elucidate the correlation between the KA protein and neuroepithelial tumors (NETs), the present study assessed the KA expression by the NETs using immunohistochemical and Western blot analyses with HFB-16 monoclonal antibody.
  • Among the 55 NETs, a moderate-to-intense KA protein immunoreactivity was observed in 8 of 8 medulloblastomas, 1 of 1 central nervous system supratentorial primitive neuroectodermal tumor (CNS supratentorial PNET), 4 of 4 retinoblastomas, 1 of 1 neuroblastoma, 8 of 8 central neurocytomas, 4 of 4 oligodendrogliomas, 4 of 4 oligoastrocytomas, 1 of 1 extraventricular neurocytoma, and 1 of 1 gangliocytoma.
  • These results indicate that the antibody HFB-16 could be a useful marker for neuronal tumors and primitive neuroectodermal tumors that may originate from immature neural progenitor cells.
  • In addition, it could be a useful tool for performing the differential diagnosis between GBs and CNS supratentorial PNET.
  • [MeSH-major] Cerebellar Neoplasms / metabolism. Guanine Nucleotide Exchange Factors / metabolism. Medulloblastoma / metabolism. Neoplasms, Neuroepithelial / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458818.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Guanine Nucleotide Exchange Factors; 0 / RASGRP3 protein, human
  •  go-up   go-down


71. Rivera AL, Pelloski CE: Diagnostic and prognostic molecular markers in common adult gliomas. Expert Rev Mol Diagn; 2010 Jul;10(5):637-49

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and prognostic molecular markers in common adult gliomas.
  • The majority of primary CNS tumors in adults are comprised of gliomas (astrocytomas, oligodendrogliomas and ependymomas).
  • The diagnosis has historically been based on the histologic appearance of these tumors.
  • In this article, we summarize the findings of important, published biomarker studies in adult gliomas and provide an overview of the practical uses of these markers in the clinical setting, as well as the current understanding of molecular gliomagenesis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / therapy. Glioma / diagnosis. Glioma / therapy
  • [MeSH-minor] Adult. Clinical Trials as Topic. Gene Expression Profiling. Humans. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20629512.001).
  • [ISSN] 1744-8352
  • [Journal-full-title] Expert review of molecular diagnostics
  • [ISO-abbreviation] Expert Rev. Mol. Diagn.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


72. Goodwin TL, Sainani K, Fisher PG: Incidence patterns of central nervous system germ cell tumors: a SEER Study. J Pediatr Hematol Oncol; 2009 Aug;31(8):541-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence patterns of central nervous system germ cell tumors: a SEER Study.
  • BACKGROUND: Incidence patterns of central nervous system (CNS) germ cell tumors (GCTs) have been reported, but the influence of underlying host risk factors has not been rigorously explored.
  • We aimed to determine in a large, population-based cancer registry how age, sex, and race, influence the occurrence of CNS GCTs in the pediatric population.
  • The cases were limited to only those with the International Classification of Childhood Cancer Xa: intracranial and intraspinal germ-cell tumors.
  • Incidence rates (per 10,000) for each sex and race were plotted for single-age groups, and then stratified by tumor location and pathology subtype.
  • Males had significantly higher rates of CNS GCTs than females.
  • Tumor location differed strikingly by sex (P<0.0001) with pineal location more common in males (61.0% vs. 15.5%).
  • Asian race was associated with a higher rate of CNS GCTs than other races.
  • CONCLUSIONS: Males have higher incidence of CNS GCTs, primarily germinomas, than females, starting in the second decade.
  • Pineal location is strongly associated with male sex, with pineal germinomas representing over half of all CNS GCTs in males.
  • These findings suggest a robust but poorly understood influence of sex, either genetic or hormonal, and race on the occurrence of CNS GCTs.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology. Neoplasms, Germ Cell and Embryonal / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Child, Preschool. Female. Humans. Incidence. Male. Middle Aged. Registries. Retrospective Studies. Sex Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19636276.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Yasuda K, Taguchi H, Sawamura Y, Ikeda J, Aoyama H, Fujieda K, Ishii N, Kashiwamura M, Iwasaki Y, Shirato H: Low-dose craniospinal irradiation and ifosfamide, cisplatin and etoposide for non-metastatic embryonal tumors in the central nervous system. Jpn J Clin Oncol; 2008 Jul;38(7):486-92
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose craniospinal irradiation and ifosfamide, cisplatin and etoposide for non-metastatic embryonal tumors in the central nervous system.
  • OBJECTIVE: The current study was conducted to evaluate the effects of low-dose craniospinal irradiation (CSI) combined with chemotherapy on non-metastatic embryonal tumors in the central nervous system (CNS), including medulloblastoma and supra-tentorial primitive neuroectodermal tumors (ST-PNET).
  • The dose to the primary tumor bed was 39.6-54 Gy.
  • CONCLUSION: Low-dose CSI and ICE chemotherapy may have a role as a treatment option for a subset of patients with non-metastatic embryonal tumors in the CNS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / therapy. Cranial Irradiation. Medulloblastoma / therapy. Neuroectodermal Tumors, Primitive / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Dose-Response Relationship, Radiation. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Infant. Male. Radiotherapy Dosage. Supratentorial Neoplasms / pathology. Supratentorial Neoplasms / therapy. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18573848.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


74. Kawai N, Okubo S, Miyake K, Maeda Y, Yamamoto Y, Nishiyama Y, Tamiya T: Use of PET in the diagnosis of primary CNS lymphoma in patients with atypical MR findings. Ann Nucl Med; 2010 Jun;24(5):335-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of PET in the diagnosis of primary CNS lymphoma in patients with atypical MR findings.
  • OBJECTIVE: The diagnosis of primary central nervous system lymphoma (PCNSL) in immunocompetent patients with atypical magnetic resonance (MR) findings such as disseminated lesions or no (non-enhancing) lesion is sometimes difficult because of mimicking other tumorous and non-tumorous diseases.
  • METHODS: We performed PET studies with FDG and MET in 17 histologically proven PCNSL and compared the uptake of FDG and MET qualitatively and quantitatively in the tumors between 12 typical and 5 atypical MR findings.
  • Semiquantitative FDG and MET uptake values (SUVmax) and quantitative FDG influx rate constant (K ( i )) in the tumors are significantly lower in atypical PCNSL compared with those in typical PCNSL.
  • [MeSH-major] Central Nervous System Neoplasms / radionuclide imaging. Lymphoma / radionuclide imaging. Magnetic Resonance Imaging. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Female. Fluorodeoxyglucose F18. Humans. Male. Methionine. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20379859.001).
  • [ISSN] 1864-6433
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18; 58576-49-1 / carbon-11 methionine; AE28F7PNPL / Methionine
  •  go-up   go-down


75. Freeman BB 3rd, Daw NC, Geyer JR, Furman WL, Stewart CF: Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. Cancer Invest; 2006 Apr-May;24(3):310-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients.
  • EGFR expression has been noted in neuroblastoma and rhabdomyosarcoma cell lines and in tumor specimens from children with Wilms tumor, osteosarcoma, and glioma.
  • Thus, gefitinib, the first marketed EGFR tyrosine kinase inhibitor, was chosen for study in children with refractory solid tumors and central nervous system (CNS) malignancies.
  • This review discusses findings from 3 clinical trials of gefitinib in children with refractory solid tumors and CNS malignancies, focusing on the clinical pharmacology of the compound.
  • Finally, the future for the use of gefitinib in pediatrics is similar to that of other molecularly targeted agents and awaits definition of tumors and patient populations in which it will be most advantageous.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Central Nervous System Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Child. Clinical Trials as Topic. Drug Resistance, Neoplasm. Humans. Receptor, Epidermal Growth Factor / drug effects. Receptor, Epidermal Growth Factor / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16809160.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; 7673326042 / irinotecan; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 67
  •  go-up   go-down


76. Sultan I, Qaddoumi I, Rodríguez-Galindo C, Nassan AA, Ghandour K, Al-Hussaini M: Age, stage, and radiotherapy, but not primary tumor site, affects the outcome of patients with malignant rhabdoid tumors. Pediatr Blood Cancer; 2010 Jan;54(1):35-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age, stage, and radiotherapy, but not primary tumor site, affects the outcome of patients with malignant rhabdoid tumors.
  • BACKGROUND: Malignant rhabdoid tumors (MRTs) are aggressive and often fatal; the Surveillance, Epidemiology, and End Results (SEER) database offers an opportunity to study this rare malignancy.
  • RESULTS: For the 229 patients included in our data, who were diagnosed from 1986 to 2005, primary tumors were located in the central nervous system (CNS) (35%), kidneys (20%), and extra-renal non-cranial sites (ERNC-MRTs) (45%).
  • Most patients with renal and CNS tumors were less than 18 years old (87% and 96%, respectively) while more than half of the patients with ERNC-MRTs (61%) were adults.
  • Among staged tumors, 23% were localized, 34% regional, and 43% distant.
  • Renal tumors had significantly more metastatic disease (47%; P = 0.006) than ERNC-MRTs.
  • Univariate and multivariate analyses showed that age at diagnosis (2-18 years), localized stage of tumors, and use of radiotherapy were significantly associated with improved survival.
  • Adults had a better outcome than young children (<2 years old) but a poorer outcome than older children (2-18 years old); tumor stage, but not radiotherapy use, affected outcome in adults.
  • CONCLUSION: Our population-based study indicates that age at diagnosis, tumor stage, and use of radiotherapy favorably impact survival rates of patients with MRTs.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radiotherapy. Kidney Neoplasms / pathology. Kidney Neoplasms / radiotherapy. Rhabdoid Tumor / pathology. Rhabdoid Tumor / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Staging. Prognosis. SEER Program. Survival Rate. Treatment Outcome. Young Adult


77. Fortin D, Desjardins A, Benko A, Niyonsega T, Boudrias M: Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. Cancer; 2005 Jun 15;103(12):2606-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
  • BACKGROUND: The treatment of malignant brain tumors is hampered by the presence of the blood-brain barrier, which limits chemotherapy penetration to the central nervous system (CNS).
  • The authors detail their experience so far with the procedure in the context of an open Phase II study in the treatment of malignant brain tumors.
  • METHODS: Patients with histologically proven malignant gliomas, primitive neuroectodermal tumors, primary CNS lymphomas, and metastatic disease to the brain were eligible.
  • The overall median survival times (MST) from treatment initiation for glioblastoma multiforme (GBM), anaplastic oligodendrogliomas, primary CNS lymphomas, and metastases were, respectively, 9.1, 13.9, not reached, and 9.9 months, whereas time to disease progression was 4.1, 9.2, 12.3, and 3.3 months.
  • CONCLUSIONS: These encouraging results prompted the authors to further refine their knowledge of the potential contribution of this procedure in the treatment of brain tumors.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Blood-Brain Barrier / drug effects. Brain Neoplasms / drug therapy. Carboplatin / therapeutic use. Infusions, Intra-Arterial. Methotrexate / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / drug therapy. Astrocytoma / pathology. Child. Disease Progression. Drug Delivery Systems. Female. Glioblastoma / drug therapy. Glioblastoma / pathology. Humans. Lymphoma / drug therapy. Lymphoma / pathology. Male. Middle Aged. Neuroectodermal Tumors, Primitive / drug therapy. Neuroectodermal Tumors, Primitive / pathology. Oligodendroglioma / drug therapy. Oligodendroglioma / pathology. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 15880378.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


78. Plesec TP, Prayson RA: Frozen section discrepancy in the evaluation of central nervous system tumors. Arch Pathol Lab Med; 2007 Oct;131(10):1532-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frozen section discrepancy in the evaluation of central nervous system tumors.
  • CONTEXT: Frozen section (FS) evaluation of central nervous system (CNS) lesions provides an assessment of specimen adequacy and facilitates triage for ancillary studies.
  • DESIGN: All CNS FS cases involving a tumor diagnosis at FS or permanent section (N = 2156) from September 1997 until June 2005 were retrospectively reviewed.
  • Nine (15.8%) of 57 discrepancies involved errors in the diagnosis of CNS lymphoma.
  • Four (7.0%) of 57 discrepancies involved errors in the overgrading of tumors.
  • CONCLUSIONS: Frozen section of CNS neoplastic processes can be highly accurate.
  • Approximately 80% of the discrepant cases were classified into 5 categories: spindle cell lesions, astrocytoma versus oligodendroglioma, differential diagnosis of CNS lymphoma, reactive versus neoplastic process, and tumor overgrading.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Diagnostic Errors / statistics & numerical data. Frozen Sections / methods. Pathology, Surgical / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Intraoperative Period. Male. Middle Aged. Reproducibility of Results. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922589.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


79. Welzel G, Fleckenstein K, Mai SK, Hermann B, Kraus-Tiefenbacher U, Wenz F: Acute neurocognitive impairment during cranial radiation therapy in patients with intracranial tumors. Strahlenther Onkol; 2008 Dec;184(12):647-54
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute neurocognitive impairment during cranial radiation therapy in patients with intracranial tumors.
  • BACKGROUND AND PURPOSE: The objective of the current study was to evaluate the acute effects of cranial radiation therapy (CNS-RT) using different radiation doses (0, 1.8, 2, 3, >or=20 Gy) on cognitive function with special emphasis on memory.
  • We assessed patients with and without intracranial tumors to distinguish between direct and indirect radiation effects on brain tissue.
  • Sixty-four patients received RT to the brain (55 with, 9 without intracranial tumor).
  • RESULTS: Patients with intracranial tumor demonstrated attention (19-38th percentile) and verbal memory scores (34-46th percentile) below the population average at baseline.
  • The average Verbal Memory score was significantly different between patients with intracranial tumor and controls both at baseline (38th vs. 58th percentile) and after irradiation (27th vs. 52th percentile).
  • Radiation dose-related deficits were seen for working memory performance in patients with intracranial tumor.
  • Patients with intracranial tumor show a deterioration of almost all memory functions with a dose-dependent impairment in working memory.
  • [MeSH-major] Attention / radiation effects. Brain / radiation effects. Brain Neoplasms / radiotherapy. Cognition / radiation effects. Cranial Irradiation / adverse effects. Memory / radiation effects. Radiotherapy / adverse effects
  • [MeSH-minor] Adult. Aged. Brain Edema / complications. Data Interpretation, Statistical. Female. Humans. Male. Middle Aged. Neuropsychological Tests. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Memory.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Life Sci. 1996;58(17):1475-83 [8622574.001]
  • [Cites] Neuropsychiatry Neuropsychol Behav Neurol. 2000 Apr;13(2):101-11 [10780628.001]
  • [Cites] Strahlenther Onkol. 2005 Mar;181(3):141-56 [15756518.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):157-65 [14701778.001]
  • [Cites] Brain Res Mol Brain Res. 1999 Jul 23;71(1):61-8 [10407187.001]
  • [Cites] Magn Reson Imaging. 1997;15(4):423-32 [9223043.001]
  • [Cites] Strahlenther Onkol. 2002 May;178(5):252-8 [12082684.001]
  • [Cites] Neuroscience. 2003;119(3):635-42 [12809684.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3470-6 [11481352.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1497-501 [11121654.001]
  • [Cites] Neurology. 2005 Jan 25;64(2):335-7 [15668434.001]
  • [Cites] Strahlenther Onkol. 2007 Aug;183(8):440-6 [17680224.001]
  • [Cites] Stereotact Funct Neurosurg. 2001;76(1):36-46 [12007277.001]
  • [Cites] Strahlenther Onkol. 2000 Dec;176(12):573-81 [11140152.001]
  • [Cites] Arch Clin Neuropsychol. 2004 Jun;19(4):497-506 [15163451.001]
  • [Cites] Exp Neurol. 2004 Aug;188(2):316-30 [15246832.001]
  • [Cites] Nat Neurosci. 2000 Apr;3(4):313-4 [10725918.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23 (18):4127-36 [15961760.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4021-7 [12874001.001]
  • [Cites] Radiother Oncol. 2003 Nov;69(2):177-82 [14643955.001]
  • [Cites] J Psychopharmacol. 2002 Mar;16(1):65-71 [11949774.001]
  • [Cites] Psychoneuroendocrinology. 2005 Apr;30(3):225-42 [15511597.001]
  • [Cites] Strahlenther Onkol. 2007 Oct;183(10):576-80 [17896090.001]
  • [Cites] J Neurosci. 1994 Apr;14(4):2047-53 [8198631.001]
  • [Cites] J Neurooncol. 1995;25(3):227-38 [8592173.001]
  • [Cites] Invest Radiol. 2003 Sep;38(9):539-49 [12960523.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):891-4 [10386647.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 15;34(5):1037-44 [8600086.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Apr;15(4):625-32 [8010261.001]
  • [Cites] Radiat Res. 2004 Jul;162(1):39-47 [15222778.001]
  • [Cites] Radiat Res. 2004 Jan;161(1):17-27 [14680400.001]
  • [Cites] Strahlenther Onkol. 2003 Jul;179(7):441-51 [12835880.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):995-9 [9869221.001]
  • [Cites] J Clin Oncol. 1995 Sep;13(9):2263-71 [7666084.001]
  • [Cites] Radiother Oncol. 1996 Oct;41(1):55-9 [8961368.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):706-13 [14966095.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):101-11 [15093905.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 24;325(4):1223-35 [15555557.001]
  • [Cites] Nat Med. 2002 Sep;8(9):955-62 [12161748.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1430-7 [12459366.001]
  • [Cites] Strahlenther Onkol. 2007 May;183(5):248-55 [17497096.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2070-5 [9215274.001]
  • [Cites] Strahlenther Onkol. 2006 Jul;182(7):382-8 [16826356.001]
  • (PMID = 19107345.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


80. Schneider DT, Zahn S, Sievers S, Alemazkour K, Reifenberger G, Wiestler OD, Calaminus G, Göbel U, Perlman EJ: Molecular genetic analysis of central nervous system germ cell tumors with comparative genomic hybridization. Mod Pathol; 2006 Jun;19(6):864-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular genetic analysis of central nervous system germ cell tumors with comparative genomic hybridization.
  • The limited information available to date regarding the genetic alterations in germ cell tumors of the central nervous system has raised concerns about their biologic relationship to other germ cell tumor entities.
  • We investigated fresh-frozen or archival tumor samples from 19 patients with central nervous system germ cell tumors (CNS-GCTs), including seven germinomas, eight malignant nongerminomatous germ cell tumors and four teratomas, using chromosomal comparative genomic hybridization to determine recurrent chromosomal imbalances.
  • All 15 malignant CNS-GCTs and two of four teratomas showed multiple chromosomal imbalances.
  • Chromosomal gains (median: 4 gains/tumor, range: 0-9 gains/tumor) were observed more frequently than losses (median: 1.6 losses/tumor, range: 0-6 losses/tumor).
  • Gain of 12p, which is considered characteristic for germ cell tumors of the adult testis, was detected in 11 of 19 tumors and 10 of 15 malignant CNS-GCTs.
  • In one tumor, gain of 12p was confined to an amplicon at 12p12, corresponding to the commonly amplified region on 12p.
  • Notably, we observed no difference in the genetic profiles of germinomatous and nongerminomatous CNS-GCTs; however, the average number of imbalances was higher in the latter group.
  • A meta-analysis comparing 116 malignant gonadal and extragonadal germ cell tumors revealed that the genomic alterations in CNS-GCTs are virtually indistinguishable from those found in their gonadal or other extragonadal counterparts of the corresponding age group.
  • These data strongly argue in favor of common pathogenetic mechanisms in gonadal and extragonadal germ cell tumors.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Genetic Testing / methods. Neoplasms, Germ Cell and Embryonal / genetics. Oligonucleotide Array Sequence Analysis / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. DNA, Neoplasm / analysis. Female. Humans. Infant, Newborn. Male. Meta-Analysis as Topic

  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607373.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


81. Gill P, Litzow M, Buckner J, Arndt C, Moynihan T, Christianson T, Ansell S, Galanis E: High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system. Cancer; 2008 Apr 15;112(8):1805-11
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system.
  • BACKGROUND: Embryonal central nervous system (CNS) tumors (medulloblastoma, cerebral neuroblastoma, pineoblastoma, and primitive neuroectodermal tumors) are rare in adults.
  • The purpose of the current study was to evaluate adult patients with embryonal CNS tumors who were treated with HDC with ASCT and compare their outcomes with those of patients who received conventional-dose chemotherapy.
  • METHODS: The authors reviewed the medical records of 23 adult patients (age >or= 18 years) who were treated at the Mayo Clinic for recurrent embryonal CNS tumors between 1976 and 2004.
  • CONCLUSIONS: Improvements in the median TTP and survival noted with the administration of HDC with ASCT, as well as the acceptable toxicity of this regimen, supports consideration of its use in adults with recurrent embryonal CNS tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Medulloblastoma / drug therapy. Neoadjuvant Therapy. Neoplasm Recurrence, Local / drug therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Carmustine / administration & dosage. Cisplatin / administration & dosage. Cohort Studies. Disease Progression. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Lomustine / administration & dosage. Male. Middle Aged. Procarbazine / administration & dosage. Retrospective Studies. Survival Rate. Thiotepa / administration & dosage. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer. 2008 Apr 15;112(8):1643-5 [18306390.001]
  • (PMID = 18300237.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 35S93Y190K / Procarbazine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 905Z5W3GKH / Thiotepa; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


82. Nasonkin I, Mahairaki V, Xu L, Hatfield G, Cummings BJ, Eberhart C, Ryugo DK, Maric D, Bar E, Koliatsos VE: Long-term, stable differentiation of human embryonic stem cell-derived neural precursors grafted into the adult mammalian neostriatum. Stem Cells; 2009 Oct;27(10):2414-26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term, stable differentiation of human embryonic stem cell-derived neural precursors grafted into the adult mammalian neostriatum.
  • Human embryonic stem cells (HESCs) are a rich source of neural precursors (NPs) for grafting, but have been questioned for their tendency to form tumors.
  • Here we studied the ability of HESC-derived NP grafts optimized for cell number and differentiation stage prior to transplantation, to survive and stably differentiate and integrate in the basal forebrain (neostriatum) of young adult nude rats over long periods of time (6 months).
  • Our findings demonstrate the long-term ability of noggin-derived human NPs to structurally integrate tumor-free into the mature mammalian forebrain, while maintaining some cell fate plasticity that is strongly influenced by particular central nervous system (CNS) niches.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cereb Cortex. 2000 Aug;10(8):729-47 [10920046.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16707-12 [18922775.001]
  • [Cites] Neuron. 2000 Dec;28(3):713-26 [11163261.001]
  • [Cites] Development. 2001 Oct;128(19):3759-71 [11585802.001]
  • [Cites] Nat Biotechnol. 2001 Dec;19(12):1129-33 [11731781.001]
  • [Cites] Nat Rev Neurosci. 2002 Apr;3(4):271-80 [11967557.001]
  • [Cites] Neuron. 2002 Aug 29;35(5):865-75 [12372282.001]
  • [Cites] J Neurosci. 2003 Jan 1;23(1):167-74 [12514213.001]
  • [Cites] BMC Neurosci. 2001;2:9 [11399205.001]
  • [Cites] J Cell Biol. 2003 Jun 9;161(5):911-21 [12796477.001]
  • [Cites] Lancet Neurol. 2003 Jul;2(7):417-24 [12849120.001]
  • [Cites] Stem Cells. 2003;21(5):521-6 [12968106.001]
  • [Cites] BMC Neurosci. 2003 Oct 22;4:27 [14572319.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12543-8 [15310843.001]
  • [Cites] Neuroscience. 1986 Oct;19(2):465-93 [3022187.001]
  • [Cites] Nature. 1990 Oct 11;347(6293):556-8 [1699131.001]
  • [Cites] Prog Brain Res. 1990;82:391-9 [1705355.001]
  • [Cites] Brain Res. 1994 Dec 30;668(1-2):211-9 [7704606.001]
  • [Cites] Dev Biol. 1995 Apr;168(2):342-57 [7729574.001]
  • [Cites] Exp Neurol. 1996 Jan;137(1):15-25 [8566206.001]
  • [Cites] Mech Dev. 1996 Sep;59(1):89-102 [8892235.001]
  • [Cites] J Neurosci. 1997 Aug 1;17(15):5858-67 [9221783.001]
  • [Cites] Nature. 1997 Dec 18-25;390(6661):680-3 [9414159.001]
  • [Cites] Genes Dev. 1998 May 15;12(10):1438-52 [9585504.001]
  • [Cites] Stem Cells. 2004;22(6):925-40 [15536184.001]
  • [Cites] Nat Biotechnol. 2005 Feb;23(2):215-21 [15685164.001]
  • [Cites] Mol Cell Biol. 2005 Mar;25(6):2475-85 [15743839.001]
  • [Cites] Nat Biotechnol. 2005 May;23(5):601-6 [15852001.001]
  • [Cites] J Neurosci. 2005 May 11;25(19):4694-705 [15888645.001]
  • [Cites] Stem Cells Dev. 2005 Jun;14(3):266-9 [15969621.001]
  • [Cites] J Neurosci. 2005 Sep 21;25(38):8714-24 [16177041.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14069-74 [16172374.001]
  • [Cites] Stem Cells. 2005 Oct;23(9):1234-41 [16002783.001]
  • [Cites] Stem Cells. 2005 Oct;23(9):1242-50 [16210408.001]
  • [Cites] Neuron. 2006 Jan 5;49(1):41-53 [16387638.001]
  • [Cites] Neuron. 2006 Jan 5;49(1):55-66 [16387639.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1319-24 [16432194.001]
  • [Cites] Stem Cells. 2006 Jan;24(1):125-38 [16100006.001]
  • [Cites] Stem Cells Dev. 2006 Apr;15(2):254-9 [16646671.001]
  • [Cites] Stem Cells. 2006 Jun;24(6):1583-93 [16543488.001]
  • [Cites] Stem Cells. 2006 Jun;24(6):1433-40 [16556709.001]
  • [Cites] Exp Neurol. 2006 Oct;201(2):525-9 [16806174.001]
  • [Cites] Curr Opin Genet Dev. 2006 Oct;16(5):455-62 [16920351.001]
  • [Cites] Transplantation. 2006 Oct 15;82(7):865-75 [17038899.001]
  • [Cites] Eur J Neurosci. 2006 Oct;24(7):1885-96 [17067292.001]
  • [Cites] Dev Cell. 2006 Dec;11(6):831-44 [17141158.001]
  • [Cites] Neurosurg Clin N Am. 2007 Jan;18(1):59-69, viii-ix [17244554.001]
  • [Cites] Stem Cells. 2007 Feb;25(2):411-8 [17038668.001]
  • [Cites] J Neurosci. 2007 Feb 21;27(8):1836-52 [17314281.001]
  • [Cites] Neurobiol Aging. 2007 Aug;28(8):1148-62 [16859812.001]
  • [Cites] Glia. 2007 Aug 15;55(11):1156-68 [17597119.001]
  • [Cites] Stem Cells. 2007 Aug;25(8):1931-9 [17478583.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e39 [17298165.001]
  • [Cites] J Neurosci. 2007 Nov 21;27(47):12787-96 [18032650.001]
  • [Cites] Cell. 2007 Nov 30;131(5):861-72 [18035408.001]
  • [Cites] Expert Opin Biol Ther. 2008 Feb;8(2):137-41 [18194070.001]
  • [Cites] Curr Protoc Neurosci. 2005 Nov;Chapter 3:Unit 3.18 [18428621.001]
  • [Cites] EMBO J. 2000 Oct 16;19(20):5460-72 [11032813.001]
  • (PMID = 19609935.001).
  • [ISSN] 1549-4918
  • [Journal-full-title] Stem cells (Dayton, Ohio)
  • [ISO-abbreviation] Stem Cells
  • [Language] ENG
  • [Grant] United States / NIDCD NIH HHS / DC / DC000232; United States / NINDS NIH HHS / NS / R01 NS045140; United States / NINDS NIH HHS / NS / NS45140-03; United States / NEI NIH HHS / EY / P30 EY001765; United States / NIDCD NIH HHS / DC / DC000232-23; United States / NIDCD NIH HHS / DC / R01 DC000232-23; United States / NIDCD NIH HHS / DC / DC005211-089002; United States / NIDCD NIH HHS / DC / R01 DC000232; United States / NIDCD NIH HHS / DC / P30 DC005211; United States / NINDS NIH HHS / NS / R01 NS045140-03; United States / NEI NIH HHS / EY / EY01765; United States / NINDS NIH HHS / NS / NS045140-03; United States / NIDCD NIH HHS / DC / P30 DC005211-089002
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Phosphoproteins; 148294-77-3 / noggin protein
  • [Other-IDs] NLM/ NIHMS193803; NLM/ PMC2906132
  •  go-up   go-down


83. Lynam LM, Lyons MK, Drazkowski JF, Sirven JI, Noe KH, Zimmerman RS, Wilkens JA: Frequency of seizures in patients with newly diagnosed brain tumors: a retrospective review. Clin Neurol Neurosurg; 2007 Sep;109(7):634-8
MedlinePlus Health Information. consumer health - Epilepsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of seizures in patients with newly diagnosed brain tumors: a retrospective review.
  • Brain tumors may lead to symptomatic epilepsy.
  • A retrospective analysis was undertaken to evaluate the frequency of seizure as the presenting symptom leading to brain tumor diagnosis in adults.
  • One hundred and forty-seven consecutive patients with newly diagnosed brain tumors were analyzed regarding the frequency of seizures as the initial presenting symptoms and those subsequently developing seizures.
  • One hundred twelve patients had primary central nervous system tumors (CNS) and 35 had metastatic lesions.
  • Astrocytomas and meningiomas were the most common primary CNS tumors in this study.
  • Seizures were a frequent presenting symptom, occurring in over 38% of those with primary brain neoplasms and 20% of those with cerebral metastases.
  • Primary location of tumor also correlated amongst primary CNS tumors and was associated with a trend in seizure risk: parietal (80%); temporal (74%); frontal (62%); and occipital (0%) (p<0.5).
  • [MeSH-major] Brain Neoplasms / complications. Epilepsy / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cross-Sectional Studies. Epilepsies, Partial / epidemiology. Epilepsies, Partial / etiology. Female. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Seizures.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17601658.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


84. Wentworth S, Pinn M, Bourland JD, Deguzman AF, Ekstrand K, Ellis TL, Glazier SS, McMullen KP, Munley M, Stieber VW, Tatter SB, Shaw EG: Clinical experience with radiation therapy in the management of neurofibromatosis-associated central nervous system tumors. Int J Radiat Oncol Biol Phys; 2009 Jan 1;73(1):208-13
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical experience with radiation therapy in the management of neurofibromatosis-associated central nervous system tumors.
  • PURPOSE: Patients with neurofibromatosis (NF) develop tumors of the central nervous system (CNS).
  • METHODS AND MATERIALS: Eighteen patients with NF with CNS tumors were treated from 1986 to 2007.
  • Progression was defined as growth or recurrence of an irradiated tumor on serial imaging.
  • RESULTS: Eighty-two tumors in 18 patients were irradiated, with an average of five tumors/patient.
  • Tumor types included acoustic neuroma (16%), ependymoma (6%), low-grade glioma (11%), meningioma (60%), and schwanomma/neurofibroma (7%).
  • CONCLUSIONS: RT provided local control, OS, and PFS rates similar to or better than published data for tumors in non-NF patients.
  • Radiation therapy should be considered in NF patients with imaging progression of CNS tumors.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / radiotherapy. Neurofibromatoses / mortality. Neurofibromatoses / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Humans. Middle Aged. North Carolina / epidemiology. Survival Analysis. Survival Rate. Treatment Outcome. Young Adult


85. Ganly I, Patel SG, Singh B, Kraus DH, Bridger PG, Cantu G, Cheesman A, De Sa G, Donald P, Fliss D, Gullane P, Janecka I, Kamata SE, Kowalski LP, Levine P, Medina LR, Pradhan S, Schramm V, Snyderman C, Wei WI, Shah JP: Complications of craniofacial resection for malignant tumors of the skull base: report of an International Collaborative Study. Head Neck; 2005 Jun;27(6):445-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complications of craniofacial resection for malignant tumors of the skull base: report of an International Collaborative Study.
  • BACKGROUND: Advances in imaging, surgical technique, and perioperative care have made craniofacial resection (CFR) an effective and safe option for treating malignant tumors involving the skull base.
  • Because of the relative rarity of these tumors, most existing data on postoperative complications come from individual reports of relatively small series of patients.
  • This international collaborative report examines a large cohort of patients accumulated from multiple institutions with the aim of identifying patient-related and tumor-related predictors of postoperative morbidity and mortality and set a benchmark for future studies.
  • Postoperative complications were classified into systemic, wound, central nervous system (CNS), and orbit.
  • Wound complications occurred in 237 (19.8%), CNS-related complications in 193 (16.2%), orbital complications in 20 (1.7%), and systemic complications in 57 (4.8%) patients.
  • CONCLUSIONS: CFR is a safe surgical treatment for malignant tumors of the skull base, with an overall mortality of 4.7% and complication rate of 36.3%.
  • The impact of medical comorbidity and intracranial tumor extent should be carefully considered when planning therapy for patients whose tumors are amenable to CFR.
  • [MeSH-major] Postoperative Complications. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. International Cooperation. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley Periodicals, Inc.
  • (PMID = 15825205.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


86. Santi M, Quezado M, Ronchetti R, Rushing EJ: Analysis of chromosome 7 in adult and pediatric ependymomas using chromogenic in situ hybridization. J Neurooncol; 2005 Mar;72(1):25-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of chromosome 7 in adult and pediatric ependymomas using chromogenic in situ hybridization.
  • Few studies have yielded reliable data that distinguish between ependymal neoplasms based on molecular genetic attributes.
  • The present study utilizes chromogenic in situ hybridization (CISH), a relatively recent hybridization technique, to retrospectively examine chromosome 7-copy number in pediatric and adult ependymomas.
  • Of the 27 hybridizations, polysomy of chromosome 7 was detected in 10 out of 15 (66%) adult ependymomas, and in only three out of 12 (25%) pediatric lesions.
  • The remaining tumors were diploid.
  • The authors conclude that (1) there are distinct genetic subsets of ependymoma, in particular, increases in copy number of chromosome 7 are almost exclusively found in myxopapillary ependymoma, and that (2) CISH is a rapid and sensitive method of stratifying morphological variants of ependymoma and potentially other central nervous system (CNS) tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 7 / genetics. Ependymoma / genetics. Ploidies. Spinal Cord Neoplasms / genetics
  • [MeSH-minor] Adult. Age Factors. Child. Child, Preschool. Chromogenic Compounds / analysis. Humans. In Situ Hybridization / methods. Infratentorial Neoplasms / classification. Infratentorial Neoplasms / genetics. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15803371.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Chromogenic Compounds
  •  go-up   go-down


87. Mühlisch J, Schwering A, Grotzer M, Vince GH, Roggendorf W, Hagemann C, Sörensen N, Rickert CH, Osada N, Jürgens H, Frühwald MC: Epigenetic repression of RASSF1A but not CASP8 in supratentorial PNET (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of childhood. Oncogene; 2006 Feb 16;25(7):1111-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic repression of RASSF1A but not CASP8 in supratentorial PNET (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of childhood.
  • Supratentorial primitive neuroectodermal tumors (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of the CNS represent a biological and clinical enigma, despite advances in both molecular techniques and clinical management for these two rare embryonal brain tumors of childhood.
  • We thus studied aberrant methylation of the genes RASSF1A and CASP8 and its consequence on expression in cell lines and primary tumors using a combination of semiquantitative methylation specific PCR (MSP), bisulfite sequencing and RT-PCR.
  • A 5' CpG-rich region of CASP8 was methylated in normal tissues and in tumors.
  • However, CASP8 showed inconsistent expression patterns in normal and tumor tissues.
  • Our results indicate that aberrant methylation of the RASSF1A promoter region may be of importance in the origin and progression of sPNET and AT/RT while the analysed 5'-CpG rich region of the CASP8 gene does not seem to play an important role in these tumors.
  • Further studies of epigenetic changes in these rare tumors are warranted as their biology remains obscure and treatment efforts have been rather unsuccessfull.
  • [MeSH-major] Brain Neoplasms / genetics. DNA Methylation. Gene Silencing. Neuroectodermal Tumors, Primitive / genetics. Rhabdoid Tumor / genetics. Teratoma / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Caspase 8. Caspases / genetics. Child. Child, Preschool. CpG Islands. Epigenesis, Genetic. Female. Humans. Hydroxamic Acids / pharmacology. Infant. Male. Promoter Regions, Genetic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16186793.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydroxamic Acids; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins; 3X2S926L3Z / trichostatin A; 776B62CQ27 / decitabine; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspases; M801H13NRU / Azacitidine
  •  go-up   go-down


88. Hu SW, Tsai KB, Yang SF, Lee KS, Chai CY: Unusual solitary fibrous tumors in the central nervous system: a report of two cases. Kaohsiung J Med Sci; 2005 Apr;21(4):179-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual solitary fibrous tumors in the central nervous system: a report of two cases.
  • Solitary fibrous tumors (SFTs) are uncommon, and most are found in the pleura.
  • SFTs of the central nervous system (CNS) are very rare.
  • Most neurosurgeons do not believe that SFTs can present as primary CNS neoplasms.
  • We report two cases, so that surgeons may recognize that this is an entity different from other spindle-cell CNS tumors.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Neoplasms, Fibrous Tissue / pathology
  • [MeSH-minor] Adult. Antigens, CD34 / analysis. Female. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15909674.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


89. de Boer AG, Verbeek JH, van Dijk FJ: Adult survivors of childhood cancer and unemployment: A metaanalysis. Cancer; 2006 Jul 1;107(1):1-11
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult survivors of childhood cancer and unemployment: A metaanalysis.
  • The purpose of this metaanalysis was to assess the risk of unemployment of adult survivors of childhood cancer compared with healthy controls and to explore prognostic factors.
  • Survivors of central nervous system (CNS) and brain tumors were nearly 5 times more likely to be unemployed (OR 4.74, 95% CI, 1.21-18.65), whereas the risks for survivors of blood or bone cancers were elevated but not found to be statistically significant (OR 1.42, 95% CI, 0.79-2.55; OR 1.97, 95% CI, 0.88-4.40, respectively).
  • Adult survivors of childhood cancer are at risk of unemployment, especially the subgroup of survivors of CNS and brain tumors.
  • [MeSH-major] Neoplasms / epidemiology. Survivors. Unemployment / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Europe. Female. Follow-Up Studies. Humans. Male. Odds Ratio. Prognosis. Retrospective Studies. Risk. Risk Factors. Time. United States

  • Genetic Alliance. consumer health - Childhood Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • [CommentIn] Cancer. 2006 Dec 15;107(12):2958-9; author reply 2959 [17096430.001]
  • (PMID = 16718655.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  •  go-up   go-down


90. Kim KE, Kim KU, Kim DC, Park JI, Han JY: Cytogenetic characterizations of central nervous system tumors: the first comprehensive report from a single institution in Korea. J Korean Med Sci; 2009 Jun;24(3):453-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic characterizations of central nervous system tumors: the first comprehensive report from a single institution in Korea.
  • The World Health Organization (WHO) classification of central nervous system (CNS) tumors incorporates morphology, cytogenetics, molecular genetics, and immunologic markers.
  • Despite the relatively large number of CNS tumors with clonal chromosome abnormalities, only few studies have investigated cytogenetic abnormalities for CNS tumors in Korea.
  • Thus, we investigated 119 CNS tumors by conventional G-banded karyotypes to characterize patterns of chromosomal abnormalities involving various CNS tumors, and 92.4% of them were cultured and karyotyped successfully.
  • Totally, 51.8% of karyotypable CNS tumors showed abnormal cytogenetic results, including neuroepithelial tumors (75.0%), meningeal tumors (71.1%), pituitary adenomas (4.2%), schwannomas (44.4%), and metastatic tumors (100.0%).
  • Abnormal karyotypes were more complex at high-grade tumors, suggesting that the karyotype reflects the biologic nature of the tumor.
  • More detailed cytogenetic and molecular characterizations of CNS tumors contribute to better diagnostic criteria and deeper insights of tumorigenesis, eventually resulting in development of novel therapeutic strategies.
  • [MeSH-major] Asian Continental Ancestry Group / genetics. Central Nervous System Neoplasms / genetics. Chromosome Aberrations
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Glioblastoma / genetics. Humans. Karyotyping. Korea. Male. Meningeal Neoplasms / genetics. Middle Aged. Neurilemmoma / genetics. Pituitary Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2000 Jun;48(2):95-101 [11083072.001]
  • [Cites] Expert Rev Neurother. 2004 Jul;4(4):649-63 [15853584.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):199-201 [11161377.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):279-84 [11807985.001]
  • [Cites] J Neurosurg. 2002 Mar;96(3):559-64 [11892633.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jun;135(2):147-59 [12127399.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Apr 1;142(1):1-7 [12660025.001]
  • [Cites] Adv Anat Pathol. 2003 Jul;10(4):212-7 [12826827.001]
  • [Cites] Childs Nerv Syst. 2003 Jun;19(5-6):270-85 [12761644.001]
  • [Cites] J Med Genet. 2003 Nov;40(11):802-6 [14627667.001]
  • [Cites] Neurosurg Rev. 2004 Jan;27(1):58-64 [12845540.001]
  • [Cites] Cancer Genet Cytogenet. 2004 May;151(1):36-51 [15120909.001]
  • [Cites] Hum Mol Genet. 1994 Aug;3(8):1393-9 [7987321.001]
  • [Cites] Oncogene. 1995 Apr 20;10(8):1521-8 [7731706.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Oct;14(2):85-96 [8527398.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Sep;90(2):109-17 [8830718.001]
  • [Cites] Cancer Res. 1996 Nov 15;56(22):5141-5 [8912848.001]
  • [Cites] Cancer Genet Cytogenet. 1997 May;95(1):1-8 [9140447.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2765-80 [9205089.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Aug;97(1):39-53 [9242217.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):598-603 [9892679.001]
  • [Cites] J Pathol. 1999 Aug;188(4):395-9 [10440750.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):137-60 [15674475.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2653-61 [15805262.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(10):1099-104; discussion 1104-5 [11129530.001]
  • (PMID = 19543509.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2698192
  • [Keywords] NOTNLM ; Central Nervous System Neoplasms / Chromosome Abnormality / Karyotype / Solid Tumor / WHO Classification
  •  go-up   go-down


91. Silvestre DC, Gil GA, Tomasini N, Bussolino DF, Caputto BL: Growth of peripheral and central nervous system tumors is supported by cytoplasmic c-Fos in humans and mice. PLoS One; 2010;5(3):e9544
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth of peripheral and central nervous system tumors is supported by cytoplasmic c-Fos in humans and mice.
  • Herein we examined phospholipid synthesis status in brain tumors from human patients and from NPcis mice, an animal model of the human disease Neurofibromatosis Type 1 (NF1).
  • PRINCIPAL FINDINGS: In human samples, c-Fos expression was at the limit of detection in non-pathological specimens, but was abundantly expressed associated to ER membranes in tumor cells.
  • This was also observed in CNS of adult tumor-bearing NPcis mice but not in NPcis fos(-/-) KO mice.
  • A glioblastoma multiforme and a malignant PNS tumor from a NF1 patient (MPNST) showed a 2- and 4- fold c-Fos-dependent phospholipid synthesis activation, respectively.
  • CONCLUSIONS: Results highlight a role of cytoplasmic c-Fos as an activator of phospholipid synthesis in events demanding high rates of membrane biogenesis as occurs for the exacerbated growth of tumors cells.
  • They also disclose this protein as a potential target for controlling tumor growth in the nervous system.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Cytoplasm / metabolism. Proto-Oncogene Proteins c-fos / biosynthesis

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1999 Dec 10;286(5447):2172-6 [10591652.001]
  • [Cites] J Neurosci Res. 2009 Aug 1;87(10):2273-81 [19267420.001]
  • [Cites] Neurochem Res. 2000 Jan;25(1):153-62 [10685615.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):109-13 [10973261.001]
  • [Cites] Genes Dev. 2000 Nov 1;14(21):2695-700 [11069886.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jan 12;280(1):9-13 [11162469.001]
  • [Cites] Cell. 2001 Feb 23;104(4):593-604 [11239415.001]
  • [Cites] FASEB J. 2001 Mar;15(3):556-8 [11259365.001]
  • [Cites] Am J Hum Genet. 2001 May;68(5):1110-8 [11283797.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(13):4369-78 [11390664.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1573-7 [11894862.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Apr 30;135(1-2):71-7 [11978395.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):616-26 [12154354.001]
  • [Cites] Trends Mol Med. 2003 Jan;9(1):19-23 [12524206.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):371-81 [14667504.001]
  • [Cites] Mol Biol Cell. 2004 Apr;15(4):1881-94 [14767061.001]
  • [Cites] Glia. 1989;2(4):223-30 [2527821.001]
  • [Cites] Nature. 1989 Aug 17;340(6234):568-71 [2505081.001]
  • [Cites] J Neurochem. 1990 Dec;55(6):1855-60 [2230799.001]
  • [Cites] Biochim Biophys Acta. 1991 Dec 10;1072(2-3):129-57 [1751545.001]
  • [Cites] Neuron. 1992 Jan;8(1):13-23 [1730004.001]
  • [Cites] Cell. 1992 Nov 13;71(4):577-86 [1423615.001]
  • [Cites] Nature. 1992 Dec 24-31;360(6406):741-5 [1465144.001]
  • [Cites] Trends Neurosci. 1995 Feb;18(2):66-7 [7537412.001]
  • [Cites] Oncogene. 1996 Feb 1;12(3):507-13 [8637706.001]
  • [Cites] J Neurosci Res. 1996 Jan 1;43(1):93-8 [8838579.001]
  • [Cites] Am J Hum Genet. 1997 Sep;61(3):512-9 [9326316.001]
  • [Cites] Brain Res Mol Brain Res. 1998 Jul 15;58(1-2):10-5 [9685570.001]
  • [Cites] J Neurochem. 1999 Sep;73(3):1228-35 [10461916.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Aug 1;214(3):263-9 [16473383.001]
  • [Cites] Oncogene. 2007 May 24;26(24):3551-8 [17160021.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10631-4 [18006802.001]
  • [Cites] J Biol Chem. 2008 Nov 7;283(45):31163-71 [18784083.001]
  • [Cites] J Neurosci Res. 2009 Mar;87(4):857-65 [18951474.001]
  • [Cites] Nature. 2009 Apr 30;458(7242):1127-30 [19407794.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • (PMID = 20209053.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-fos
  • [Other-IDs] NLM/ PMC2832012
  •  go-up   go-down


92. Soares Leães CG, Filho AP, Pereira Lima JF, Dallago CM, Batista RL, Barbosa-Coutinho LM, Ferreira NP, da Costa Oliveira M: Hyperprolactinemia and immunohistochemical expression of intracellular prolactin and prolactin receptor in primary central nervous system tumors and their relationship with cellular replication. Brain Tumor Pathol; 2007;24(2):41-6
Genetic Alliance. consumer health - Galactorrhoea-Hyperprolactinaemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperprolactinemia and immunohistochemical expression of intracellular prolactin and prolactin receptor in primary central nervous system tumors and their relationship with cellular replication.
  • The role of prolactin (PRL) in the CNS remains uncertain.
  • We evaluated the presence of hyperprolactinemia, intracellular prolactin (ICP), and prolactin receptor (PRL-R) in primary CNS tumors, and their relationship with cellular replication with a prospective cross-sectional study of 82 consecutive patients with primary CNS tumors admitted for neurosurgical resection between October 2003 and September 2005.
  • The frequencies of hyperprolactinemia, ICP, and PRL-R were similar across the several histological types of CNS tumors.
  • Hyperprolactinemia and intracellular presence of PRL and PRL-R were common findings in this population, suggesting a role for PRL in CNS tumor genesis.
  • [MeSH-major] Central Nervous System Neoplasms / complications. Central Nervous System Neoplasms / metabolism. Hyperprolactinemia / complications. Prolactin / metabolism. Receptors, Prolactin / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Proliferation. Child. Cross-Sectional Studies. Female. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Male. Middle Aged. Thyrotropin / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095129.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Prolactin; 9002-62-4 / Prolactin; 9002-71-5 / Thyrotropin
  •  go-up   go-down


93. Telarović S, Telarović S, Relja M, Franinović-Marković J: Impact of war on central nervous system tumors incidence--a 15-year retrospective study in Istria County, Croatia. Coll Antropol; 2006 Mar;30(1):149-55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of war on central nervous system tumors incidence--a 15-year retrospective study in Istria County, Croatia.
  • The aim of study was to analyze epidemiological features of central nervous system (CNS) tumors diagnosed in Istria County, Croatia, with a particular emphasis on incidence dynamics during the wartime (1991-1995).
  • The data were extracted from the medical records of patients with CNS tumors admitted to the Department of Neurology of Pula General Hospital in the period from the 1st January 1986 to the 31st December 2000, N = 364.
  • The analyzed tumor-related variables included clinical manifestation, localization, and applied diagnostic and therapeutic methods.
  • Primary tumors were separated from the metastatic, and the latter were analysed with respect to their site of origin.
  • The lowest incidence of CNS tumors (10 patients) was reported in 1990, and the highest (42 patients) in 1993.
  • The incidence dynamics of CNS tumors showed a rapidly progressive increase over the 1991-1995 period, followed by the return to average values.
  • Therefore, we analyzed other factors that may have contributed towards the rapid increase in the number of CNS tumors, such as its coincidence with the war or psychotrauma.
  • The results confirm the observational clinical hypothesis of an extreme increase in the number of CNS tumors during the period under consideration.
  • [MeSH-major] Central Nervous System Neoplasms / etiology. Warfare
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Combined Modality Therapy. Croatia / epidemiology. Female. Humans. Incidence. Male. Medical Records. Middle Aged. Retrospective Studies. Sex Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16617590.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


94. Villano JL, Virk IY, Ramirez V, Propp JM, Engelhard HH, McCarthy BJ: Descriptive epidemiology of central nervous system germ cell tumors: nonpineal analysis. Neuro Oncol; 2010 Mar;12(3):257-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Descriptive epidemiology of central nervous system germ cell tumors: nonpineal analysis.
  • Central nervous system (CNS) germ cell tumors (GCT) have not been epidemiologically well described.
  • Our study describes 2 population-based series of nonpineal CNS GCT.
  • Data on all primary (malignant and nonmalignant) CNS (ICD-O-3 sites: C70.0-C72.9, C75.1-C75.3) GCT diagnosed between 2000 and 2004 from the Central Brain Tumor Registry of the United States (CBTRUS) and on all malignant GCT diagnosed between 1992 and 2005 from the Surveillance, Epidemiology, and End Results (SEER) were analyzed.
  • For children and young adults, most tumors were malignant (86.8% and 89.0%, respectively), whereas for adults, more than half were nonmalignant (56.8%).
  • In SEER, the frequency of malignant GCT in the CNS (2.5%) was greater than that in the mediastinum (2.1%).
  • Of 408 malignant CNS GCT, 216 (52.9%) were nonpineal.
  • Overall relative survival for nonpineal CNS malignant GCT was 85.3% at 2 years, 77.3% at 5 years, and 67.6% at 10 years.
  • Nonpineal CNS GCT show no significant gender preference, yet have outcomes similar to pineal GCT.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology. Neoplasms, Germ Cell and Embryonal / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Child. Child, Preschool. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Registries. SEER Program. United States / epidemiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2585-92 [10561326.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):121-30 [18287340.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1171-6 [10725628.001]
  • [Cites] Oncologist. 2000;5(4):312-20 [10964999.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Sep;59(9):815-21 [11005262.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7268-76 [11585765.001]
  • [Cites] Int J Clin Oncol. 2001 Aug;6(4):183-91 [11706556.001]
  • [Cites] Brain Tumor Pathol. 2001;18(2):115-22 [11908867.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Oct;57(4):487-500 [12354131.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):846-53 [14990640.001]
  • [Cites] Pediatr Blood Cancer. 2004 Aug;43(2):126-33 [15236278.001]
  • [Cites] Am J Clin Pathol. 1976 Apr;65(4):450-4 [178171.001]
  • [Cites] J Neurosurg. 1985 Aug;63(2):155-67 [2991485.001]
  • [Cites] Int J Androl. 1987 Feb;10(1):43-9 [3034798.001]
  • [Cites] J Neurosurg. 1987 Jul;67(1):65-70 [2439668.001]
  • [Cites] AJNR Am J Neuroradiol. 1989 Sep-Oct;10(5):1039-44 [2476011.001]
  • [Cites] Pediatr Pathol. 1990;10(1-2):231-41 [2156245.001]
  • [Cites] Chest. 1991 Feb;99(2):472-9 [1846573.001]
  • [Cites] J Neurosurg. 1991 Apr;74(4):545-51 [1848284.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Dec;5(6):1189-209 [1663939.001]
  • [Cites] Radiat Med. 1992 Mar-Apr;10(2):55-61 [1320768.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):229-45 [8270446.001]
  • [Cites] Neuropediatrics. 1994 Feb;25(1):26-32 [8208347.001]
  • [Cites] Med Pediatr Oncol. 1995 Jun;24(6):368-72 [7536294.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):446-55 [9046301.001]
  • [Cites] J Neurooncol. 1997 Mar;32(1):71-80 [9049865.001]
  • [Cites] Cancer. 1997 Aug 15;80(4):681-90 [9264351.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1792-7 [9351549.001]
  • [Cites] Childs Nerv Syst. 1999 Mar;15(2-3):119-26; discussion 127 [10230668.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):133-7 [10413166.001]
  • [Cites] Bull N Y Acad Med. 1950 Jul;26(7):440-60 [15426876.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] J Neurosurg. 2005 Dec;103(6 Suppl):524-30 [16383251.001]
  • [Cites] Obstet Gynecol. 2006 May;107(5):1075-85 [16648414.001]
  • [Cites] Urology. 2006 Aug;68(2):402-5; discussion 405 [16904461.001]
  • [Cites] Neurology. 2007 May 15;68(20):1668-73 [17502547.001]
  • [Cites] Childs Nerv Syst. 2008 Jan;24(1):71-8 [17906866.001]
  • [Cites] J Neurooncol. 1999 Aug;44(1):71-6 [10582672.001]
  • (PMID = 20167813.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2940596
  •  go-up   go-down


95. Attard TM, Giglio P, Koppula S, Snyder C, Lynch HT: Brain tumors in individuals with familial adenomatous polyposis: a cancer registry experience and pooled case report analysis. Cancer; 2007 Feb 15;109(4):761-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumors in individuals with familial adenomatous polyposis: a cancer registry experience and pooled case report analysis.
  • They are at an increased risk of brain tumors, including cerebellar medulloblastoma, when compared with the general population (Brain Tumor Polyposis-BTP Type 2).
  • Genotype-phenotype correlations between APC gene mutations and central nervous system (CNS) tumors have, thus far not been successful.
  • METHODS: The authors analyzed their established hereditary CRC Registry for brain tumors in FAP pedigrees (56 families, 213 individuals), pooled their patients with BTP and known APC mutations with those reported thus far elsewhere, and compared the resulting mutation distribution of FAP-BTP with the mutation distribution for APC mutations in the US.
  • RESULTS: Twenty-eight patients from 24 families were accrued, the most common brain tumor in BTP was medulloblastoma (60%) predominantly in females (12:5) under the age of 20 (mean age 14.7 SD 9.2).
  • Analysis of the pooled APC mutation data by Chi-square test of association shows an odds ratio of 3.7 (P < .005) for all brain tumor subtypes and 13.1 (P < .001) for medulloblastoma in patients harboring segment 2 APC mutation (codons 679-1224) compared to nonsegment 2 mutation.
  • CONCLUSIONS: In patients with FAP and identifiable APC gene mutation, CNS tumors, especially medulloblastoma which developed in most cases during childhood, are more common in females with FAP and APC gene mutation in codons 686-1217.
  • [MeSH-major] Adenomatous Polyposis Coli / complications. Adenomatous Polyposis Coli Protein / genetics. Brain Neoplasms / complications. Mutation / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Codon. Female. Humans. Male. Pedigree. Registries


96. Behdad A, Perry A: Central nervous system primitive neuroectodermal tumors: a clinicopathologic and genetic study of 33 cases. Brain Pathol; 2010 Mar;20(2):441-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system primitive neuroectodermal tumors: a clinicopathologic and genetic study of 33 cases.
  • Central nervous system (CNS) primitive neuroectodermal tumors (PNETs) include supratentorial, brain stem, and spinal cord tumors with medulloblastoma-like histopathology.
  • After re-diagnosis of three infantile cases as atypical teratoid/rhabdoid tumor (AT/RT), 33 remaining CNS PNETs were retrieved for clinicopathologic and fluorescence in situ hybridization studies.
  • We conclude that in CNS PNET: (i) routine application of INI1 immunohistochemistry helps rule out AT/RT, particularly in infants;.
  • (iii) involvement of CNS parenchyma by Ewing sarcoma/peripheral PNET is rare enough that EWS gene testing is not necessary unless significant dural involvement is present; and (iv) both anaplastic/large cell features and polysomies of 2 and 8 are associated with more aggressive clinical behavior.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Neuroectodermal Tumors, Primitive / genetics. Neuroectodermal Tumors, Primitive / pathology. Spinal Cord Neoplasms / genetics. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aneuploidy. Child. Child, Preschool. Chromosomes, Human, Pair 2. Chromosomes, Human, Pair 22. Chromosomes, Human, Pair 8. Female. Humans. Infant. Male. Middle Aged. Nuclear Proteins / genetics. Oncogene Proteins / genetics. RNA-Binding Protein EWS / genetics. Rhabdoid Tumor / diagnosis. Rhabdoid Tumor / genetics. Rhabdoid Tumor / pathology. Teratoma / diagnosis. Teratoma / genetics. Teratoma / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19725831.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / MYCN protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins; 0 / RNA-Binding Protein EWS
  •  go-up   go-down


97. Biswas S, Burke A, Cherian S, Williams D, Nicholson J, Horan G, Jefferies S, Williams M, Earl HM, Burnet NG, Hatcher H: Non-pineal supratentorial primitive neuro-ectodermal tumors (sPNET) in teenagers and young adults: Time to reconsider cisplatin based chemotherapy after cranio-spinal irradiation? Pediatr Blood Cancer; 2009 Jul;52(7):796-803
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-pineal supratentorial primitive neuro-ectodermal tumors (sPNET) in teenagers and young adults: Time to reconsider cisplatin based chemotherapy after cranio-spinal irradiation?
  • BACKGROUND: Supratentorial PNET (sPNET) are rare CNS tumors of embryonal origin arising in children and adults.
  • METHODS: Medical records were reviewed to gather demographic and clinical data about all embryonal CNS tumors in children and adults from 2001 to 2007.
  • Tumor pathology, clinical management and survival data were also assessed, particularly as regards those patients who received the Packer chemotherapy regimen for either sPNET or MB.
  • RESULTS: Eleven patients (five children and six adults) were identified with non-pineal sPNET, three children with pineal sPNET, and 19 patients (18 children and 1 adult) with MB.
  • There was no difference in overall survival (OS) rates between pediatric and adult sPNET.
  • We suggest that it is time to reconsider the use of this regimen in teenage and young adult non-pineal sPNET and to investigate the utility of alternative approaches.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebellar Neoplasms / therapy. Cranial Irradiation. Medulloblastoma / therapy. Neuroectodermal Tumors, Primitive / therapy. Supratentorial Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Cisplatin / administration & dosage. Follow-Up Studies. Humans. Lomustine / administration & dosage. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome. Vincristine / administration & dosage. Young Adult

  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19202566.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


98. Laughton SJ, Merchant TE, Sklar CA, Kun LE, Fouladi M, Broniscer A, Morris EB, Sanders RP, Krasin MJ, Shelso J, Xiong Z, Wallace D, Gajjar A: Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial. J Clin Oncol; 2008 Mar 1;26(7):1112-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial.
  • PURPOSE: To estimate the cumulative incidence of specific hormone deficiencies and the influence of hypothalamic-pituitary (HP) axis radiation dose in a cohort of children with embryonal brain tumors treated with risk-adapted craniospinal irradiation (CSI), conformal primary site irradiation, and high-dose chemotherapy.
  • CONCLUSION: Pediatric patients with CNS embryonal tumors are at high risk for treatment-related hormone deficiencies.
  • [MeSH-major] Adrenocorticotropic Hormone / deficiency. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Human Growth Hormone / deficiency. Hypothyroidism / etiology. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / radiotherapy. Spinal Cord / radiation effects. Thyrotropin / deficiency
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cohort Studies. Cranial Irradiation. Female. Hematopoietic Stem Cells. Humans. Male. Pituitary Gland / drug effects. Pituitary Gland / radiation effects. Prospective Studies. Risk Factors


99. Carpentino JE, Hartman NW, Grabel LB, Naegele JR: Region-specific differentiation of embryonic stem cell-derived neural progenitor transplants into the adult mouse hippocampus following seizures. J Neurosci Res; 2008 Feb 15;86(3):512-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Region-specific differentiation of embryonic stem cell-derived neural progenitor transplants into the adult mouse hippocampus following seizures.
  • Embryonic stem (ES) cells can generate neural progenitors and neurons in vitro and incorporate into the adult central nervous system (CNS) following transplantation, suggesting their therapeutic potential for treating neurological disorders.
  • However, our understanding of the conditions that direct ES-derived neural progenitor (ESNP) migration and differentiation within different regions of the adult CNS is incomplete.
  • To examine the potential for ESNPs to incorporate into the adult hippocampus and differentiate into hippocampal neurons or glia following seizure-induced damage, we compared the fates of ESNPs after they were transplanted into the CA3 region or fimbria 1 week following KA-induced seizures.
  • Hippocampal grafts in mice not subjected to seizures displayed a marked tendency to form tumors, and this effect was more pronounced in the DG than in the fimbria.
  • Taken together, these data suggest that seizures induce molecular changes in the CA3 region and DG that promote region-specific neural differentiation and suppress tumor formation.

  • MedlinePlus Health Information. consumer health - Seizures.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17918739.001).
  • [ISSN] 1097-4547
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS042826; United States / NINDS NIH HHS / NS / R01 NS042826-05; United States / NINDS NIH HHS / NS / NS42826
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Convulsants; 0 / Excitatory Amino Acid Agonists; SIV03811UC / Kainic Acid
  •  go-up   go-down


100. Sigauke E, Rakheja D, Maddox DL, Hladik CL, White CL, Timmons CF, Raisanen J: Absence of expression of SMARCB1/INI1 in malignant rhabdoid tumors of the central nervous system, kidneys and soft tissue: an immunohistochemical study with implications for diagnosis. Mod Pathol; 2006 May;19(5):717-25
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of expression of SMARCB1/INI1 in malignant rhabdoid tumors of the central nervous system, kidneys and soft tissue: an immunohistochemical study with implications for diagnosis.
  • Malignant rhabdoid tumors are high-grade neoplasms of the central nervous system (CNS), kidneys and soft tissue that usually occur in children.
  • The histologic diagnosis of malignant rhabdoid tumor depends on identification of characteristic rhabdoid cells-large cells with eccentrically located nuclei and abundant, eosinophilic cytoplasm-and immunohistochemistry with antibodies to vimentin, keratin and epithelial membrane antigen.
  • In most malignant rhabdoid tumors, the SMARCB1/INI1 gene, located in chromosome band 22q11.2, is inactivated by deletions and/or mutations, so genetic diagnosis is often possible.
  • We assessed SMARCB1/INI1 expression in 17 rhabdoid tumors and 57 other tumors of the CNS, kidney or soft tissue using immunohistochemistry.
  • In total, 12 brain, three renal and two soft tissue rhabdoid tumors were examined along with four glioblastomas, four pilocytic astrocytomas, four oligodendrogliomas, two ependymomas, two choroid plexus papillomas, five pituitary adenomas, four germinomas, four renal carcinomas with Xp11.2 translocations, two clear cell sarcomas, two Wilms' tumors, one renal medullary carcinoma, two desmoplastic small round cell tumors, two alveolar rhabdomyosarcomas, two embryonal rhabdomyosarcomas, one low-grade chondrosarcoma, two extraskeletal myxoid chondrosarcomas, one mesenchymal chondrosarcoma, four malignant peripheral nerve sheath tumors, five metastatic carcinomas and four epithelioid sarcomas, two primary and two metastatic.
  • The neoplastic cells of all rhabdoid tumors, the four epithelioid sarcomas and the renal medullary carcinoma did not express SMARCB1/INI1 by immunohistochemistry; neoplastic cells of all other tumors expressed SMARCB1/INI1.
  • Immunohistochemistry to assess expression of SMARCB1/INI1 may be useful in the diagnosis of rhabdoid tumors of the CNS, kidneys and soft tissue.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. DNA-Binding Proteins / biosynthesis. Kidney Neoplasms / pathology. Rhabdoid Tumor / pathology. Soft Tissue Neoplasms / pathology. Transcription Factors / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Child. Child, Preschool. Chromosomal Proteins, Non-Histone. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Infant. Infant, Newborn. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16528370.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  •  go-up   go-down






Advertisement